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GLOSSARY 
PTB: Pulmonary Tuberculosis  
PTB/HIV:Co-infection of the Human Immunodeficiency Virus and Pulmonary Tuberculosis 
MDG: Millennium Development Goals 
HIV/AIDS: Human Immunodeficiency Virus/ AcquiredImmune-Deficiency Syndrome 
MDR-TB: Multi-Drug Resistant Tuberculosis 
DOTS: Directly Observed Treatment Strategy 
PR: Pulmonary Rehabilitation 
HRQoL: Health Related Quality of Life 
NTCP: National TB Control Plan 
TB: Tuberculosis 
LTBI: Latent Tuberculosis Infection 
COPD: Chronic Obstructive Pulmonary Disease 
CASE DETECTION: newly diagnosed PTB case are reported to the national surveillance system 
INCIDENCE RATE: The rate of newly diagnosed cases of a particular disease in a specific 
population over a defined time period 
CLINICAL IMPROVEMENT: Parameters that were tested did not show statistical significance at 
the end of the six week period but did have a positive effect on the clinical presentation of the 
participant. 
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ABSTRACT: 
PURPOSE:To determine whether a community based rehabilitation exercise programme had 
an effect on pulmonary function, exercise tolerance and Health Related Quality of Life (HRQoL) 
in patients diagnosed with Pulmonary Tuberculosis (PTB).RELEVANCE:The prevalence of PTB in 
South Africa is one of the highest in the African continent. Assessing the effectiveness of the 
programme could provide further methods in improving compliance to pharmaceutical 
medication as well as an improvement in the morbidity experienced after diagnosis of 
PTB.PARTICIPANTS:Randomly selected participants with the confirmed diagnosis of PTB in the 
absence of additional lung disease, cardiac and ambulatory problems were included into study 
at a PTB clinic situated in Khayelitsha, Cape Town. METHODS:The study was conducted using a 
randomized control trial. The intervention group was given a home based pulmonary 
rehabilitation programme for the duration of six weeks while the control group was given a 
self designed information leaflet with no intervention. ANALYSIS:Means and standard 
deviations were calculated where applicable. Normally distributed data between the control 
and intervention group were analyzed using the Pearson’s Chi-Square and Fisher’s exact tests. 
Data that was not normally distributed was analyzed using the Two-sample Wilcoxon rank-sum 
(Mann-Whitney test). Correlation were also investigated in the intervention and control 
groups.RESULTS:Although not statistically significant, clinical improvement was greater in the 
HRQoL of the intervention group. At the end of the sixth week, the reading for FEV1 was 
statistically significant (p>0.02) in the intervention group. CONCLUSION:Clinical improvement 
was seen in the intervention group over the six week period with the control group showing 
only slight improvements in the areas tested. It can be concluded that a home based 
pulmonary rehabilitation programme does have a clinical impact on lung function, exercise 
tolerance and HRQoL. KEYWORDS:Pulmonary Tuberculosis, Home Based Pulmonary 
Rehabilitation.FUNDING ACKNOWLEDGEMENTS:National Research Foundation, University of 
Cape Town 
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CHAPTER ONE 
INTRODUCTION 
1.1) Prevalence of Pulmonary Tuberculosis globally and nationally 
South Africa today is ranked 5th in the world for the number of new cases of Pulmonary 
Tuberculosis (PTB) in conjunction with Human Immunodeficiency Virus/Acquired Immune-
Deficiency Syndrome (HIV/AIDS) (WHO, 2007a). Several systems and strategies have been 
identified and incorporated into many health systems to aid in the management of the disease 
as well as to improve the wellbeing of the affected patients. The eight Millennium 
Development Goals (MDG) were developed by the World Health Organisation (WHO) in 2001 
to provide countries around the world with a framework for national development; and set 
targets to be achieved in allocated timeframes by which progress can be measured (WHO, 
2006a).  
The 6th target of the MDG set out to halt and reverse the incidence of diseases such as PTB as 
well as HIV/AIDS and malaria. This specific goal aims to achieve a smear-positive case 
detection rate of approximately 70%, and up to 85% of successful treatment by 2015 (WHO, 
2007b).  In 2002, the total number of PTB cases registered in South Africa was 54 364 
compared to 46 368 in 2001, which indicated a 15% increase in a year (SA Department of 
Health, 2005). In the report published by WHO (2007), the total number of newly diagnosed 
PTB cases was found to be 490 per 100 000 population, showing an increase in the number of 
new cases from 2000, which was 482 per 100 000 population, excluding the patients 
diagnosed with co-morbidity of HIV/AIDS in the Southern Africa region. 
According to statistics published in 2008, PTB was one of the five leading causes of death in 
South Africa and the leading cause of death within the age groups 15-49 years and 50-64 years 
(Stats SA, 2008). The report published by the City of Cape Town in conjunction with the 
Metropole District Municipalities and the Provinicial Government of the Western Cape (2003), 
found that the 24,075 cases that were recognized in the City of Cape Town during 2002 were 
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found in the Khayelitsha (20%), Nyanga (16%) and Oostenberg (12%) areas. These 
areasconstitute almost half of the burden in the Metropole region. Nationally, the number of 
patients that were newly diagnosed with PTB was the highest in the district of the Overberg 
Region (86.6%) of the Western Cape, and the lowest in the district of Alfred Nzo (40.7%) of the 
Eastern Cape (Health Systems Trust 08/09).  
The target set for 2015 for the achievement of the MDGs will most likely not be met due to the 
number of patients undiagnosed with PTB, the co-infection of PTB/HIV as well as the 
occurrence of MDR-TB (SA Department of Health, 2005). Interventions for patients diagnosed 
with PTB have focused on micro-bacterial cure with no long term plan implemented to address 
the morbidities experienced as a result of the disease. This can be seen as a potential problem 
in the near future as patients will continue to suffer from the effects of the disease should an 
intervention not be implemented to combat the increase in morbidity even though a micro-
bacterial cure has been achieved. 
1.2)Challenges encountered in the management of Pulmonary Tuberculosis 
Despite the number of resources that has gone into the management of PTB, not enough 
attention has been given to the physical, emotional and financial effects that most patients 
experience as a result of being diagnosed with the disease and the medication used as part of 
the treatment regimen (Maguire et al, 2009). Pulmonary Tuberculosis not only affects the 
physical attributes of the patient but recent studies have shown that the disease affects 
patients socially, emotionally as well as financially (Dhuria et al, 2008). Multiple challenges 
have been encountered in the management of PTB in the country. The report published by the 
South African Department of Health (2004) highlighted the main challenges experienced in PTB 
control, namely delayed health seeking behaviour in patients that present with PTB symptoms 
to primary health care facilities, delayed case detection of PTB, and high incidence of non-
compliance to PTB treatment. For the purpose of this thesis, three main challenges 
encountered in the management of PTB are discussed below. 
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1.2.1)Adherence to treatment 
Biomedical and psycho-socio-economic factors as highlighted by Ukpe (2007) affects 
adherence to the prescribed treatment regimen. Non-adherence in turn increasesprobability 
of the occurrence of MDR-TB which will only further increase a continually growing incidence 
rate. According to Grimwood et al (2006), who conducted a survey by the South African 
Medical Research Council in 2001/2002, found that there was a strong connection between 
patients who had previously failed to complete the required treatment, non-compliance to the 
prescribed medication and the development of MDR-TB. 
South Africa is one of 27 countries with a high burden of MDR-TB with a prevalence of 1.6% in 
newly diagnosed PTB patients and 6.6% in patients that have defaulted from treatment 
(Grimwood et al, 2006).  
In another South African study conducted by Loveday et al (2007) which looked at the factors 
that might play a contributing role to the non-compliance of the essential medication, reports 
that poor diet as a result of low income, overcrowding in the informal settlements as well as 
substance abuse could contribute to the spread of PTB. The majority of the patients diagnosed 
with PTB are in the working class population of the community (Geetharamani et al, 2001) and 
the resultant loss of income would cause delay in diagnosis and treatment. The loss of income 
would affect the family as a whole and thus contribute to the already escalated non-
compliance of the PTB medication (Geetharamani et al, 2001). 
1.2.2)Implementation of programmes 
The incorporation of the Directly Observed Treatment Strategy (DOTS) into the management 
of patients undergoing treatment for PTB is expected to lower the growing number of new 
cases detected, but factors such as unemployment, poverty, a lack of proper housing and non-
compliance have a significantly negative impact on the success of the programme (SA 
Department of Health, 2007). Other factors such as a lack of trained staff in the management 
of TB patients, lack of resources, inadequate political assistance, poor laboratory services, 
inadequate management of patients diagnosed with Multi-drug Resistant Tuberculosis (MDR-
TB) and patients diagnosed with co-morbidity of PTB and HIV/AIDS have a major impact on the 
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successful execution of the DOTS programme as well as the achievement of the MDG’s by 
2015 (WHO, 2005). Although the establishment of the MDGs has set an international standard 
which each country has been encouraged to meet in the prescribed time, the aforementioned 
factors may well contribute to rendering the 2015 6th MDG unachievable.  
1.2.3)Community involvement in the management of Pulmonary 
Tuberculosis 
The MDGs not only place emphasis on the detection and cure rate, but the “Stop TB Strategy” 
(2006b) implemented by WHO in 2006 incorporates the involvement of the community in the 
management of patients diagnosed with PTB. Health systems have incorporated community 
support structures in community based centres to assist in high burdened areas that are low in 
resources and to assist in the compliance of patients to the treatment regimen.  The National 
Tuberculosis Strategic Plan for South Africa (2007-2011) drawn up by the SA Department of 
Health, highlighted the importance of community participation in the movement to increase 
awareness of the growing problem of the spread of PTB. 
Community support includes trained members rom the community assisting in the execution 
of the DOTS programme as well as providing a support structure to those patients on 
treatment (Dick et al, 1996). Community and patient empowerment are considered central to 
a human rights approach to the care for PTB patients as well as the ultimate prevention of PTB 
(WHO, 2006b). The empowerment of PTB patients should improve their capacity to better 
control their own health, their ability to assist other PTB patients in improving their own lives, 
as well as their ability to assist healthcare professionals involved in PTB control programmes 
thus improving their QoL (WHO, 2006b). Not only should the community according to Man et 
al (2004) be able to play a role in the management of patients while on the DOTS system but 
community members should be able to make a difference in the health status of those in the 
community after PTB treatment. This is in line with the report of Sagbakken et al (2008) who 
identified barriers and enablers in the management of TB treatment in Ethiopia. 
Globally, an increasing degree of awareness has been placed on the morbidities experienced 
during and after PTB treatment (Guo et al, 2009; Dhuria et al, 2008; Corless et al, 2006) and 
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the possible implementation of physiotherapy related interventions to address the increasing 
degree of morbidity (Ghosh et al, 2006). In South Africa, there has been little focus on 
physiotherapy related interventions, especially at community level. 
1.3)Role of physiotherapy 
Post treatment sequelae of PTB patients have included abnormal pulmonary functions 
affecting, among others, forced vital capacity (FVC), forced expiratory volume in one second 
(FEV1), and the ratio of FEV1 to FVC (Singla et al, 2009). It was therefore recommended that the 
post-treatment pulmonary rehabilitation of TB patients should be an integral part of PTB 
management program to improve the impact of the program in the community. Literature has 
reported that physiotherapy in the form of exercise training is an important component in the 
rehabilitation of patients with PTB (Yoshida et al, 2006). Pulmonary Rehabilitation is reported 
to be the most accepted method of non-pharmacological treatment in patients with PTB 
(Ciobanu et al, 2007; Ries, 2008; Ries et al 2007). Recent studies report that PR not only assists 
the patient with management of the symptoms characterized by the disease but also improves 
functional activities (Ries, 2008). Earlier studies confirmed what Ries (2008) had stated with 
regards to an improvement in the exercise tolerance and HRQoL being shown after undergoing 
an intervention in the form of a pulmonary home programme for patients diagnosed with 
pulmonary disease (Cambach et al, 1997). Pulmonary rehabilitation inclusive of upper and 
lower limb exercise was shown to be the most beneficial to patients suffering from lung 
disease (Lake et al, 1990). The inclusion of isolated peripheral muscle conditioning in a home 
based rehabilitation programme proved to be accepted by patients in the home environment 
and improved conditions of breathlessness and ventilation during exertion (Clark et al, 1996). 
1.4) Significance of the Study 
The prevalence of PTB in South Africa is one of the highest in the African continent. Assessing 
the effectiveness of the home based pulmonary rehabilitation programme in patients 
diagnosed with PTB  could provide further methods in improving compliance to 
pharmaceutical medication as well as an improvement in the morbidity experienced after 
diagnosis of PTB. 
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1.5)Aim of the study 
The intention of this study was to determine whether a home based pulmonary rehabilitation 
programme, consisting of physiotherapy interventions, would assist in the improvement of 
HRQoL, lung function as well as exercise tolerance after undergoing a6 week rehabilitation 
programme designed for the patient to execute at home, in line with the recommendation of 
Griffiths et al (2000) that an ideal length of a rehabilitation program is 6-8 weeks.  
1.5.1)Objectives of the study 
The objectives formulated from the aim of the study were structured to establish a 
relationship between the possible improvements in the patients’ ability by compliance with 
the home based exercise programme. The objectives are listed as follows: 
 To describe the demographic profile of the participants included into the study 
 To determine the baseline HRQoL, pulmonary functions and exercise tolerance among PTB 
participants. 
 To determine whether adherence to a six-week home based rehabilitation programme 
improves the functional ability of the participants as measured by a six-minute walk test. 
 To determine whether an improvement in the HRQoL could be attributed to his/her 
compliance with a six week home-based pulmonary rehabilitation programme measured 
by a HRQoL questionna re. 
 To establish whether compliance to a six week home-based pulmonary rehabilitation 
programme would show improvements in baseline measurements of lung function 
parameters. 
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CHAPTER 2: 
LITERATURE REVIEW 
2.1)Incidence of PTB Globally: 
The United Nations (2007) estimated that 8.8 million new cases of Pulmonary Tuberculosis 
(PTB) had been registered in 2005 of which a staggering 7.3 million were reported in sub-
Saharan Africa as well as in four Asian countries. As indicated in the MDG Report by the United 
Nations (2007) as many as 1.6 million people died of PTB of which 195,000 people were 
infected with HIV in 2005. 
Alarming figures published by World Health Organization(WHO) (2007(b)) excluding patients 
diagnosed with the co-infection of PTB/HIV were 255 per 100 000 new cases of PTB that were 
registered in developing regions across the globe; which is a great difference compared to 16 
per 100 000 in developed regions in 2005 (United Nations, 2007). 
According to the WHO report published in 2003, thefollowing reasons could be attributed to 
the global increase in the burden of PTB:  
 The disregard of accurate case detection and the proper cure of the patients diagnosed 
with TB by national and international governments. 
 The widening socio-economic gap in selected developing countries and the associated 
poverty that can be attributed to the marginalized income brackets. 
 The effects of the HIV pandemic and the disintegration of the health system in countries 
that have been subjected to severe economic emergency or civil unrest.  
2.2)Incidence of PTB nationally: 
Statistics South Africa (2008) found that between the year 1997 and 2002 the main contributor 
to the increase in the mortality rate was tuberculosis (TB), and specifically Pulmonary 
Tuberculosis (PTB). According to the statistics obtained during the sameperiod, individuals 
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with the common infection of PTB, experienced an increase in the number of deaths  from 20 
364 in 1997 to 54 364 deaths in 2002 SA Department of Health, 2005). 
Since the implementation of the National TB Control Programme (NTCP) in 1995, the number 
of reported PTB cases in South Africa has steadily increased. The implementation of the NTCP 
provided a means by which to identify PTB cases that have not been diagnosed hence the 
increase in case numbers (SA Department of Health, 2005).  
Almost 14 000 newly registered PTB cases were reported in Cape Town alone, which increased 
to 26 754 cases in 2005. The incidence rate of PTB also had a similar trend with numbers that 
dramatically increased from 521/100 000 in 1997 to 874/100 000 in 2005 (Western Cape 
Department of Health, 2006).  
2. 3)Challenges in the management of PTB 
Numerous factors can be attributed to the steady increase in the incidence of PTB, namely: 
poverty among individuals in the lower income bracket, immigration from countries with a 
high prevalence of PTB, inadequate health care infrastructure to manage individuals diagnosed 
with PTB and the co-infection of PTB and HIV (Maher andRaviglione, 2005; Loveday et al, 
2007).   
A greater degree of morbidity and mortality is experienced by individuals with the co-infection 
of PTB/HIV which results in a delay in seeking medical management (Meintjies et al, 2008). The 
health seeking behaviour of PTB suspected patients and those suffering from the co-infection 
of PTB/HIV are negatively affected by the current poor health care infrastructure in South 
Africa. Delay in seeking medical treatment due to the stigmatization of PTB with HIV, inevitably 
results in hospitalization (Loveday et al, 2007). Defined primarily as a disease of poverty, PTB is 
responsible for the increase in morbidity compared to any other communicable disease other 
than HIV/AIDS (WHO, 2006b). In a study conducted by Loveday et al (2007) in Kwa-Zulu Natal, 
it was found that 65% of the respondents in the evaluation of the National Tuberculosis 
Control Plan (NTCP) walked to the nearest treatment centre with an average time of 45 
minutes taken to get to the clinic. A further 36% were too ill to walk to adhere to medical 
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appointments at the clinic. This would affect the compliance to any programme, and especially 
the Directly Observed Treatment Strategy(DOTS) as patients are required to visit clinic daily. If 
they are too ill and have to travel far distances, as well as spend long times waiting at the 
health care centre for medical management, theymight end up not going (Loveday et al, 2007). 
 Another South African study conducted in Limpopo found that patients diagnosed with MDR-
TB had severe lung dysfunction even after the completion of treatment (De Valliere and 
Barker, 2004). Similarly, De Valliere and Barker (2004) reported that patients experienced a 
decrease in lung function and were not able to cope with activities that were previously 
performed on a daily basis. The aforementioned authors concluded therefore that 
management inclusive of diagnostic investigations and pharmaceutical management needed 
to focus more on the long term prospect of morbidity. Morbidity as a result of PTB, often leads 
to a vicious cycle of slow recovery and a loss of income, contributing to additional dependency 
on family and government structures for support (Sagbakken et al, 2008). 
Pulmonary Tuberculosis more commonly seen where poverty prevails, populations suffer from 
malnutrition, low access to medical facilities and overcrowding (Sanchez-Perez et al, 2001), will 
continue to contribute to the increasing degree of morbidity (Sanchez-Perez et al, 2001). 
Morbidities of PTB diagnosed patients include decreased HRQoL (Marra et al, 2004; Guo et al, 
2009 Maguire et al, 2009), impaired lung function (Chamla, 2004; Pasipanodya et al, 2007; 
Chang et al, 1999; Maguire et al, 2009) and impaired exercise tolerance (Phillips et al, 1989; 
Maguire et al, 2009).In light of the information provided by Loveday et al (2007) and Sanchez-
Perez et al (2001), an intervention that will address the physical and emotional needs of 
patients without the additional medical costs will be vital in combating the poor medical 
management experienced by some of the patients at the clinic which would result in 
defaulting from treatment. In providing poor medical management, health care facilities aid in 
the unrelenting burden of PTB as well as the development of Multi-Drug Resistant Tuberculosis 
(MDR-TB) (Singh et al, 2007).  
According to Statistics South Africa (2008), the diagnosis of PTB inclusive of MDR-TB was the 
leading cause of death in the age groups 15-49 and 50-64. The age-group of 15-49 had the 
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highest number of individuals who were diagnosed with MDR-TB (n=509) as the cause of death 
(Stats SA, 2008). The eligible work force comprise of individuals who fall into the 15-60 age 
group (Mahery andProudlock, 2008) which in light of the high mortality rate published by 
Statistics South Africa (2008) would have a serious economical and social impact on the 
working population as well as the financial income of the nucleus family (Sumartojo, 1993; 
Dye, 2006). Individuals who are included into the eligible work force usually have to prioritize 
between taking the prescribed medication and staying in employment to provide an income 
for the family (Portwig andCouper, 2006). According to the study conducted by Portwig 
andCouper (2006), providing an income usually takes priority over adhering to the medication. 
This inevitably leads to non-adherence to the treatment regimen, resulting in the development 
of MDR-TB and the increase of morbidity. “The impact of the diagnosis of PTB has a negative 
effect on the ability to work and the execution of activities of daily living while on treatment as 
well as once treatment has been completed.” (Chamla, 2004). Grimwood et al (2006) 
supported the established link between patients that had previously failed to complete the 
treatment, non-compliance to the prescribed medication and the development of MDR-TB as 
described by Portwig andCouper (2006). 
When discharged, patients were not physically able to get to the clinic to receive further 
medical management, too weak to access hospital services and did not have the strength to 
remain at the clinic waiting for medical attention (Loveday et al, 2007). 
2.4)Current management of Pulmonary Tuberculosis 
The historically used methods of diagnosis have often resulted in patient care delay with the 
dangerous possibility of the increase in the possible spread of PTB in the household as well as 
the community (Meintjes et al, 2008; Dheda et al, 2010). The conventional use ofdiagnostic 
methods including sputum smear staining (WHO, 2008; Western Cape Department of Health, 
2006) and culture testing (De Villiers and Toms, 2005) have been replaced with more advanced 
diagnostic tests that enable the clinician to receive results more rapidly with the added 
assurance of increased sensitivity and accurate case detection (Nyendak et al, 2009; Nwokedi 
andJahun, 2008; Dheda et al, 2010).  
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Although diagnostic testing and drug therapy have been changed and adapted to the 
management of the rapidly advancing disease, the pharmaceutical management has however 
not addressed the impact on the long term management of patients diagnosed with either PTB 
or MDR-TB.Therefore additional interventions should be included that would address the 
morbidities experienced by the infected patients after the prescribed medication (Ghosh et al, 
2006).  
Interventions besides the pharmaceutical therapy incorporated into the compulsory 
management of patients diagnosed with PTB is the DOTS implemented by the NTCP in 1995 
(SA Department of Health, 2005). Many international initiatives implemented globally such as 
“The Stop TB Strategy”, implemented by WHO in 2006b, highlights the key treatment aspects 
that needs to be achieved for the successful integration of the MDGs (WHO, 2009). The MDGs 
consist of eight goals to be achieved by 2015 that address the chief global developmental 
challenges. The sixth goal specifically highlights the proportionof PTB to be decreased in 
relation to detection rate and the cure rate of patients suffering from tuberculosis under the 
Directly Observed Treatment Strategy (DOTS). Concerns have been expressed that this goal 
may not be reached in Sub-Saharan Africa by 2015 as proposed(SA Department of Health, 
2005) 
The DOTS programme does not merely ensure the compliance of the patient on medication; it 
builds a relationship and understanding between the care provider and the patient as well as 
focuses on the importance of adherence to medication and a sense of duty to the community 
(FriedenandMunsiff, 2005). Wood et al (2007) evaluated the effectiveness of the DOTS control 
programme in a high burdened HIV and PTB community within sub-Saharan Africa. The study 
found untreated PTB in 9% of the study population of which 5% were previously undiagnosed. 
In conjunction with the lack of resources, poor managerial skills and a lengthened period of 
exposure in the high burdened area especially among HIV-positive individuals, the DOTS 
control programme was reported to be ineffective without the incorporation of an additional 
intervention.  
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2.5)Holistic Management 
According to Hansel et al (2004), the primary aim regarding the management of PTB has been 
to decrease the prevalence of the disease. Historically research conducted focused on the 
pathology of PTB, with minimal focus on the impact the disease had on patients’ HRQOL. More 
recently there has been a paradigm shift in research towards focusing on the morbidity and 
other side-effects experienced by patients diagnosed with PTB (Guo et al, 2009; Dhuria et al, 
2008; Corless et al, 2006). 
Patients that undergo treatment for the diagnosis of PTB, often experience severe side-effects 
that compromise the compliance to medication for the recommended six to eight month 
duration of the treatment regimen (Zaleskis, 2006). Known side-effects of the essential anti-TB 
drugs include peripheral neuropathy, sleepiness, lethargy, various gastro-intestinal, vestibular 
and reticular conditions (Zaleskis, 2006); and decreased lung volumes (Plit et al, 1998).  
Hnizdoet al (2000) found that PTB causes chronic lung impairment after contraction of the 
disease with a steady increase in the severity with each re-current episode. Lung dysfunction 
was found in 96.8 % in patients and with 90.3% experiencing negative changes in lung volumes 
and capacities with the diagnosis of chronic fibrocavernous tuberculosis (Nefedov et al, 2008). 
Patients diagnosed with a respiratory deteriorating disease often present with increased work 
of breathing, muscular atrophy, despair and dietary alterations that play a part in the 
continuous cycle of inactivity and the physiological decline that could even be experienced at 
rest (Prabhudesi, 2009). Pulmonary Tuberculosis patients without the co-infection of HIV are 
suspected to have vast lung destruction, cavitationsand upper lobe involvement as seen in the 
chest radiograph (Harries et al, 2001).   
A recent  study conducted by Pasipandoya et al (2007) compared the impairments suffered by  
patients diagnosed with Latent Tuberculosis Infection (LTBI) and patients diagnosed with 
PTBthat had already undergone 20 weeks of treatment. The aim of the study was to determine 
the extent to which patients with PTB suffered as a result of the disease and how it could be 
attributed to the primary diagnosis of PTB. Objective measurements that were used to 
measure the pulmonary function were Forced Vital Capacity (FVC), Forced Expiratory Volume 
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in one second (FEV) and the FVC/FEV1 ratio. In the study, patients diagnosed with PTB did 
indeed have a greater pulmonary impairment as measured by the FEV1,FVC readings and 
FEV1/FVC ratiocompared to the group with LTBI. The data collected among patients with PTB 
suggested that due to the possible development of a future debilitating lung disease, life 
expectancy and the quality of life could be negatively affected (De Valliere and Baker, 2004).  
2.5.1)Health related Quality of Life 
Although subsequent research in the area has identified numerous issues which impact on the 
PTB sufferer’s HRQOL, research into implementing these factors have been slow (Marra et al, 
2004). This has been partially due to the difficulty in a standardized definition of Quality of Life 
(QoL) (Patrick and Erikson, 1993; Bach andMcDaniel 1994). Ferrans (1992) divided the broadly 
used term QoL into five different domains that would encompass the definition of QoL. The 
domains include: 
 The ability to socially connect with individuals in the work environment as well as the 
home environment. 
 Overall emotional state of well-being. 
 Contentment with the progress made in life with regards to the work environment and 
social environment. 
 The accomplishment of personal goals obtained. 
 The comparison of life currently compared to previous illness or disability experienced. 
To decrease the broad spectrum of QoL, Wood-Dauphinee andKuchler (1992) suggested that 
aspects of QoL be limited to areas that encompass the health of the patient being assessed. 
According to WHOQOL (1995), the concept of HRQoL can be measured by the effect illness or 
disability has on the patients’ activities of daily living, behaviour, the way they feel about their 
own health and limitations experienced by the illness or disability. Morbidities expressed in 
QoL do not sufficiently accommodate the limitations experienced in activities of daily living 
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and over-all welfare.Therefore the evaluation using HRQoL would shed better light on those 
particular areas of interest (Guo et al, 2009). 
O’Connell et al (2003) found that with regards to patients with the co-infection of PTB/HIV, 
women, older age groups and individuals who have a lower education level, had a lower QoL 
as a result of their inability to obtain their previous level of function. Similarly a study 
conducted by Deribew et al (2009)which assessed the QoL of patients with the co-infection of 
PTB/HIV supported the suggestion of O’Connell et al (2003) who stated that depression due to 
the inability to function optimally and falling into the lower income bracket were contributors 
to the decrease in the domains of physical health, social and environmental sectors. Those 
individuals that fall into the lower income bracket often do not have the means by which to 
seek further medical help for the morbidities experienced (Sanchez-Perez et al, 2001). 
The need to incorporate the measurement of the HRQoL into the management of PTB need to 
be established due to the concept of determining health status beyond the normal indicators 
of mortality and morbidity (The WHOQOL GROUP, 1995; Chamla, 2004). The HRQoL should be 
the focus point for health care professionals (Lohr, 1988; Greenfield and Nelson, 1992; Wilson 
and Cleary, 1995). 
In the study conducted by Dhingra and Rajpal (2003), patients diagnosed with PTB and extra-
pulmonary tuberculosis were recruited into a study that evaluated the efficacy of a HRQoL 
questionnaire especially designed for tuberculosis patients. This was the first questionnaire to 
be specifically designed for the assessment of QoL in tuberculosis patients. The EQ-5D which 
was developed by WHO in 1990,is a standardized assessment tool for the assessment of 
HRQoL. The instrument has been validated in different countries including South Africa (Jelsma 
et al, 2003b).The EQ-5D assesses how the patient feels about their own health with regard to 
functioning ability under the following sub-headings: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression.  
For the duration of the prescribed treatment, patients suffering from the diagnosis of PTB have 
to deal with many psychological, emotional and financial circumstances which would affect 
their well-being during the course of their illness (Dhingraand Rajpal, 2003). A study conducted 
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by Muniyandi et al (2007)in the developing country of India,evaluated the HRQoL among PTB 
patients after completing the prescribed treatment to be clinically curedand found that the 
physical well-being score was significantly lower in participants aged 45 years and older 
(P<0.05), participants who did not have any formal education (P<0.01) and those who were 
unemployed (P<0.01). The study conducted by Muniyandi et al (2007) study may be an 
indication for studies that focus on holistic management of PTB patients which includes their 
long term rehabilitation. 
2.5.2)Inclusion ofPulmonary Rehabilitation 
The morbidity experienced by the PTB patients not only extends to the emotional aspect but 
has a greater negative influence on the physical aspect as supported by Chamla (2004) who 
found that patients’ diagnosed with PTB in comparison to a control group had a lower HRQoL 
with the physical components being more affected than the mental components of the 
assessment. The author attributed the decrease in the physical components to the effect PTB 
has on the physical health of the patients. Pulmonary Tuberculosis patientswho underwent a 
thoracoplasty experienced a greater limitation in exercise capacity than patients diagnosed 
with fibrosingalveolitis, chronic bronchitis and scoliosis(Phillips et al,1989). The authors noted 
that the patients were limited in both dynamic lung volumes and respiratory frequency due to 
a decrease in their ventilatory capacity, thus affecting their exercise ability. The co-infection of 
PTB/HIV however also had a huge negative effect on the physical functioning of PTB diagnosed 
patients (Loveday et al, 2008). 
According to Aggarwal (2010), the incorporation of non-pharmaceutical interventions into the 
management of patients diagnosed with PTB could result in an improved functional health 
status without the preceding physiologic improvements. Numerous authors recommended 
physiotherapy in the form of exercise training and pulmonary rehabilitation as the most 
accepted method of non-pharmacological treatment in patients with post-pulmonary 
tuberculosis sequelae (Yoshida et al, 2006;Pesut et al, 2008Ries, 2008; Ries et al 2007).  
“The aim of the rehabilitation programme administered by the Physiotherapy profession for 
patients suffering from lung disease is to incorporate change by which patients are able to 
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make lifestyle adjustments that will be maintained for a long period of time” (Evans & Morgan, 
2007).  
Physiotherapists according to Garrod (2003), play an important role in the administration, 
prescription, execution and maintenance of a pulmonary rehabilitation programme. The 
pulmonary rehabilitation programme not only  includes all the medical disciplines in the care 
of patients that have been diagnosed with a respiratory disease, it involves administering an 
intervention programme tailored and designed to improve physical and social well-being as 
well as independence (Man et al, 2004).  
Benefits seen in patients who have undergone pulmonary rehabilitation included a decrease in 
the utilization of the medical health services as well as the morbidity probability (British 
Thoracic Society Statement, 2001; Man et al, 2004) while improvements in exercise tolerance, 
HRQoL, dyspnoea, the health condition of the patient and activities of daily living are 
experienced  (Evans and Morgan, 2007). 
Pulmonary rehabilitation since its inception in 1895 by Charles Denison, has largely focused on 
the rehabilitation of the patients diagnosed with COPD as mentioned by Cambach et al (1997). 
Cambach et al (1997) evaluated the efficacy of a 3 month rehabilitative intervention 
programme inclusive of pharmaceutical management with the control group only receiving the 
pharmaceutical management. The rehabilitation programme that was prescribed to the 
patients included components such as breathing techniques, clearance of mucus, exercises 
that included work for both the upper and lower limbs, recreational activities that would prove 
essential in the maintenance of the results obtained after the rehabilitation programme, 
relaxation techniques incorporated into activities of daily living and education of the patient. 
The Cambach et al (1997) study found that both asthmatic and COPD patients improved in the 
exercise tolerance and QoL after undergoing a rehabilitation programme that consisted of 
components focusing on each section of a rehabilitation programme. 
Several pioneering studies have mentioned the impact of early mobilization on the HRQoL and 
health status of the patient diagnosed with PTB. Other treatment techniques utilized in the 
management of the patients include education of the disease, ambulatory rehabilitation, 
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pulmonary rehabilitation in the form of breathing techniques and incorporation of effective 
clearance of sputum techniques (Goldberg and Berner, 1953; Nacman and Dressler, 1961; 
Cohen and Blacker, 1962; Paley et al, 1956).  
In another early study pertaining to pulmonary rehabilitation, patients diagnosed with COPD 
were recruited to test the impact of a low intensity peripheral muscle conditioning 
rehabilitation programme to be performed in the home environment (Clark et al, 1996). The 
authors’ rationale behind selecting a low impact programme for the rehabilitation was to 
minimize the need for equipment so that the exercises could be performed at home and to 
enable the execution of the exercises to be incorporated into the activities of daily living. The 
programme consisted of low impact exercises for the lower limbs, upper limbs, abdominals 
and a component of endurance training was also included. The home programme given to the 
intervention group was completed on a daily basis with a training log to be kept while the 
control group did not receive a programme to do but were requested to continue with their 
daily routines. The study found that the intervention group had greater improvements in 
endurance of specific muscles as well as conditioning as a whole.  
A study conducted by Ando et al (2003) researched the difference that pulmonary 
rehabilitation made in patients diagnosed with post-tuberculosis lung disorder and COPD. The 
outcome measures that the researcher used were the 6 min-walk test, the Medical Research 
Council dyspnoea grade, activity score and the transition dyspnoea score. The pulmonary 
rehabilitation programme consisted of breathing exercises which included pursed lipped 
breathing, slow-breathing in the supine and sitting positions, and re-education of the 
breathing technique with relaxation. The pulmonary rehabilitation programme also consisted 
of exercise training for the upper and lower extremities for 30 minutes and daily level walking 
for 15 minutes. The lung function results showed similar improvement in both the post-
tuberculosis group and the COPD group after pulmonary intervention in the lung function 
testing as well as the results from the 6 minute-walk test. As a result of the improvement 
noted in both the post-tuberculosis and COPD group, it was concluded that intervention in the 
management of lung disorders other than that of COPD, is indeed beneficial. 
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A study conducted by Niederman et al (1991) the effect of a pulmonary rehabilitation 
programme was evaluated on thirty-three patients with known chronic lung disease and a 
decreased ability to exercise due to dyspnoea.  They found that significant improvements were 
noted in the exercise endurance and the decline in the ventilatory equivalent for oxygen 
consumption (VE/VO2 max) during maximal exercise after the study was conducted. The study 
concluded that an improvement was noted in the FEV1 reading of 17 out of the 33 patients 
recruited into the study and that a rehabilitation programme would benefit patients diagnosed 
with respiratory lung disease with the expectation of seeing results. 
Lisboa et al (1997) investigated the effect of inspiratory muscle training on exercise capacity in 
chronic airflow limitation. The researchers hypothesized that by recruiting the inspiratory 
muscles an improvement will be noted in the exercise performance of the patients. Those 
patients working under 30% of peak maximal pressure showed the most improvement in the 
performance of daily living, relief of dyspnoea and an improvement of exercise capacity as 
measured in the 6 minute-walk test. Although Lisbo  et al (1997) used recruitment of the 
inspiratory muscles and Clark et al (1996) used a programme that consisted of low impact 
exercises, the two researchers used different physical components to set up a rehabilitation 
programme in which the goals that were met were similar in relation to an improvement in the 
ability to perform activities of daily living, breathlessness and exercise capacity. 
While Lisboa et al (1997) investigated the effects of inspiratory muscle recruitment, Wijkstra et 
al (1995) combined the recruitment of the inspiratory muscles, upper limb training, breathing 
training, relaxation techniques and exercise training into a home rehabilitation programme for 
43 patients diagnosed with severe airflow obstruction. Outcome measures included baseline 
lung function testing, quality of life questionnaire and a cycle ergometer test. A combination of 
the two rehabilitation components, namely exercise training and pulmonary rehabilitation 
produced similar results to the studies conducted by Lisboa et al (1997) and Clark et al (1996). 
Although patients do benefit from the execution of a pulmonary rehabilitation programme, 
Wijkstra (1996a) brought to light the expenses incurred by the patient during hospitalization. 
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According to Wijkstra (1996a) it would therefore be more beneficial to the patient to undergo 
rehabilitation in the home or community setting. 
2.5.3)Community Based Rehabilitation 
Rehabilitation of patients has shifted from the in-patient and out-patient setting to the 
incorporation of the home environment because of limited space in the hospital rehabilitation 
setting,family and friends support, rehabilitation cost being cheaper, and the option of 
integrating the pulmonary rehabilitation programme into activities of daily living (Wijkstra et 
al, 1996b). Factors such as discharge, distance from the hospital and the cost of treatment 
sessions play a positive role in patients participating in home based pulmonary rehabilitation 
programmes (Garrod, 2003). By decreasing the dependency on the medical health system, 
support from the community and family in the home setting becomes important in assisting 
the patient to adhere to the pulmonary rehabilitation programme in the community or home 
setting (Garrod, 2003; Ries et al, 1995). 
The effectiveness of the home based pulmonary rehabilitation translated into significant 
changes in QoL, exercise tolerance (Wijkstra et al, 1994; Ries et al, 1995; Goldstein et al, 1994), 
rate of perceived breathlessness after performing household chores, muscle fatigue after 
performing activities and being able to walk long distances independently (Ries et al, 1995). 
Loveday et al (2008) further went on to say that the use of efficient home based care with the 
involvement of the community in the management of patients diagnosed with PTB could have 
important health benefits to the patient as well as the family and the community as a whole. 
Community and patient empowerment are considered central to a human rights approach to 
care for PTB patients as well as the prevention of TB (WHO, 2008).  The Community 
Involvement in Tuberculosis Care and Prevention Document (WHO, 2008) highlights the 
important role family, friends and care-providers play in the foremost administrators of health 
care as well as the essential role in health promotion in the patients and in the community 
itself as a long term goal for the duration of PTB patients.  
The long term effects of a home rehabilitation programme were further evaluated by 
Wijkstraet al (1995) who found that QoL was sustained for 18 months, with monthly 
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physiotherapy visits after discharge from the hospital. The improvement of the QoL were 
attributed to the responsibility the patients took upon themselves to perform the home 
rehabilitation programme. According to Wijkstra (1996b) patients should be made less 
dependent on health professionals for the execution of rehabilitative services in management 
of chronic diseases and made to be more self-reliant and include those closest to the patient 
to assist in the management process. Ghosh et al (2006) supported the view of a non-
pharmaceutical management programme in the form of physiotherapy to aid in the alleviation 
of morbidities in PTB diagnosed patients. 
By involving the community in the treatment and management of PTB, it allows the 
community to develop as a unit by addressing the morbidities experienced by PTB patients,  
finding solutions and rehabilitating patients diagnosed with PTB to alleviate the long term 
burden of the PTB epidemic. Alleviationnot only for the community but for the PTB patient as 
well (City of Cape Town PTB Control Programme, 1997-2002).  
2.6) Conclusion 
In reviewing the literature, similarities are found in the medical management of patients with 
the PTB disease. Management includes prompt diagnosis, pharmaceutical management and 
discharge of the patient into amaintenance plan incorporated by the DOTS programme. The 
long term management of the patientsis however unsubstantial even though evidence has 
been found that HRQoL, lung function and exercise toleranceare negatively affected post 
treatment. Treatment strategies need to be implemented to address the morbidities 
experienced by patients with PTB to improve the long term implications of the disease and 
thereby allow for a continuum of health care post chemotherapy and to improve the current 
health system. 
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CHAPTER 3: 
METHODOLOGY 
3.1)Research setting: 
The primary research setting wasKhayelitsha, a suburb in Cape Town. It has one of the highest 
prevalence of PTB and HIV infection on a national as well as on international scale (MSF TB 
Report, 2009).  
The Community Health Centre (CHC) situated in the area of Khayelitsha, Site B opened a PTB 
clinic that constantly monitors the management and progress of PTB patients admitted or 
referred to the unit from the CHC or neighbouring health care facilities. The area has one of 
the highest incidences of PTB in the Western Cape, which is a direct result of the living 
conditions and high density of inhabitants living in the district. Three main sections make up 
the healthcare complex known as the Site B Khayelitsha Day Hospital, namely the Community 
Health Centre (CHC), the maternity unit, and the Ubuntu PTB and HIV clinic. On a daily basis 
the clinic is filled with patients receiving medication for PTB and anti-retroviral medication for 
the treatment of Human Immunodeficiency Virus (HIV). Patients who attend the clinic do not 
receive any form of physiotherapy while undergoing treatment for the diagnosis of PTB. The 
Ubuntu Clinic situated in the informal settlement ofKhayelitsha was chosen as the research 
setting because of the high prevalence of PTB in the area. 
3.2)Aim of the study: 
The aim of the study was to determine whether adherence to a six-week home based 
pulmonary rehabilitation programme(PRP) improved the baseline measurements of 
HRQoL,lung function and exercise tolerance in patients suffering from PTB. 
3.3)Study design: 
A single, blinded randomized control study design (Wedzicha et al, 1998) was used to assess 
the effectiveness of the home based PRP on HRQoL, pulmonary function and exercise 
tolerance. 
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3.4)Recruitment of participants: 
All patients attending the Ubuntu Clinic, Site B for a consecutive 4 month period with 
confirmed laboratory test of active PTB were eligible to participate in the study. The student, 
being the primary researcher, had the help of two assistants, namely: The Independent 
Primary Research Assistant (IPRA) and Independent Secondary Research Assistant (ISRA), each 
of which had their own responsibilities to fulfil.   
The ISRA, a previous attendee of the clinic had knowledge of the administrative infrastructure 
as well as the programme that each participant had to undertake and complete. The ISRA was 
responsible for the recruitment of the participants from the treatment area where all the 
participants remained until attended to by the nursing staff. The ISRA gave a brief introduction 
and description of the study and what would be required of the participant. If the participant 
agreed to participate in the study, the ISRA led the participant to the IPRA for further 
management. The IPRA had a clear understanding of the procedure of the study as well as the 
objectives that had to be met.  
The IPRA assessed whether the participant was eligible to be included in the study. The total 
number of participants assessed for eligibility was 130 of which only 102 participants gave 
consent to participate in the study. For participants who met the inclusion criteria, a detailed 
explanation of the study and procedure was provided before the informed consent document 
(Appendix A) that required the participants to disclose medical and personal information was 
signed. The IPRA was responsible for randomly allocating the participants into either the 
intervention or the control group, making the follow-up appointments, explaining the exercise 
programme for the duration of the six weeks as well as answering any questions that the 
participants might have about the study. 
3.4.1)Process of group allocation 
The IPRA randomly allocated the participants into either the intervention or control groups by 
selecting a folded coloured piece of paper from a box. Each colour represented either the 
control or intervention group into which the participant would be allocated. The participants 
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that were allocated into either the intervention or control group were recorded and listed on a 
separate document (Appendix B) kept by the IPRA.  
Once the participants had been randomly allocated, both the intervention and control groups 
had 51 participants respectively. All participants in the intervention and control groups 
received the allocated treatment protocol that had been set out for the group.  During the 
course of the six week programme, some participants in the control group (n=18) and the 
intervention group (n=17) were lost to follow-up and discontinued intervention due to various 
reasons (See Fig 4.1). In the control group nine participants were lost to follow-up 
appointments and could not be telephonically contacted during the weeks between follow-up 
appointments.  Nine participants discontinued the intervention for numerous reasons, 
including being admitted to other CHC’s because of accessibility and transfer to a secondary 
hospital for further management. The intervention group lost one participant to follow-up 
appointments being missed and 16 participants discontinued the intervention for reasons 
including admission to CHC’s that were more accessible, transfer to a secondary hospital for 
further management, time constraints due to work and personal problems and having to 
relocate to the Eastern Cape for an undisclosed amount of time. Thus the control group had 33 
participants and the intervention group had 34 participants who completed the prescribed 
intervention for each group.  
3.4.2)Instrumentations: 
The information required to draw up the demographic profile of the participants was recorded 
on a self-developed demographic questionnaire (Appendix C). The demographic information 
collected included age, gender and race. Other information also in the questionnaire were 
included years of formal education, occupation, marital status, diagnoses and treatment 
regimens. 
Data pertaining to HRQoL was collected using the EQ-5D Questionnaire (Appendix D). The 
questionnaire was used to measure HRQoL at baseline, week three and week six. The EQ-5D 
included a self-evaluation of the participants perceived health on that particular day with 
regard to five different domains, namely: mobility, self-care, usual activities, pain/discomfort 
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and anxiety/depression (Jelsma et al, 2003a). The five different domains are subdivided into 
categories, namely: no problems, some problems and difficulty performing the activity (Jelsma 
et al, 2003a). 
Data obtained with regard to pulmonary function, exercise tolerance, rate of perceived 
exertion, and the necessary information with regards to the follow-up appointments were 
recorded on a self-developed data capture sheet (Appendix E). Each participant had a separate 
data capture sheet that was used to record measurements from baseline to the sixth week. 
Before the participant commenced the testing procedure and performed the exercise 
programme, the Physical Activity Readiness Questionnaire(Par-Q) (Appe dix F) was used to 
measure the ability of the participant to perform physical activity without the presence of 
cardiac problems.  
An automotive desktop spirometer (MINATO AUTOSPIRO-model no. AZ-505) was used to 
measure the forced expiratory volume in one second (FEV1) and Forced Vital capacity (FVC) of 
participants included in the study. Pulmonary function testing was performed at baseline, 
week three and week six (Yoshida et al, 2006). The spirometer had been calibrated before the 
commencement of the study. To ensure the participants were compliant to the exercise 
programme given to them, a Xhosa checklist (Appendix G) and a English checklist (Appendix H) 
was attached to the exercise programme, which they marked off on a daily basis the activities 
they carried out for the day. The participants were required to present the checklist at the 
follow-up appointments to determine how compliant they were to the exercise programme. 
The exercise programme (Appendix I) was designed to incorporate cardiovascular, low-impact 
activities and pulmonary rehabilitation components in a manner that would be easy for the 
participants to understand and execute. The component of cardiovascular training in the form 
of walking was to be done on a daily basis for a period of 15 minutes. The participants were 
instructed to initially perform the walking component at their own pace and gradually increase 
the pace each day. The participants were required to perform the activities independently as 
far as they could manage. The participant was then required to perform low-impact activities 
that would recruit the upper and lower limb muscles followed by pulmonary rehabilitation 
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activities that would aid in lung expansion, effective expectoration of sputum, recruitment of 
respiratory muscles and initiation of controlled breathing. Postural correction was also 
incorporated into the exercise programme.  
3.4.3)Pilot Study: 
The procedure was tested in the setting of the secondary hospital for a period of two weeks. 
The reliability and the validity of the selected instruments was assessed as well as the 
procedure at the secondary hospital. Reliability of the selected instruments was determined by 
testing the instrument on different patients (n=20) over the two week period, following the 
same procedure for each individual who was recruited. The scores were assessed to determine 
whether a correlation was found over the two week period. The instruments used in the study 
were found to be both reliable and valid for the procedure. The pilot study was performed 
prior to the data collection period to additionally ascertain the following: 
 Whether the self-developed demographic questionnaire was appropriate with 
regards to the population being assessed. 
 Whether the prescribed exercise programme and check list were understood by the 
participants recruited into the study. 
 The effectiveness of participants using a spirometer to measure the lung function 
capability. 
 The effectiveness of the six-minute walk test to determine exercise tolerance of the 
participants. 
 The duration of the initial assessment of the participants with regard to completion 
of the EQ-5D Questionnaire and collecting of the baseline functions. 
 On completion of the pilot study the following conclusions were drawn from the 
information obtained: 
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 During the piloting of the exercise programme, it was identified that the exercise 
programme needed to be translated and explained in the participants preferred 
language. 
 Illustrations needed to be included in the PRP in order to remember the exercises 
that had been explained as well as link the text to the illustration that would be 
shown. 
 The data capture sheet needed additional questions to complete the profile of the 
participants. 
The following questions were included in the demographic questionnaire to complete the 
profile of the participants: 
 Additional questions were included into the demographic questionnaire with 
regards to: 
 The primary diagnosis and co-morbidity of each participant 
 The treatment regimen being received by the participant 
3.5)Testing Procedures: 
In the section below, a detailed explanation of the procedures for collecting the data with 
regards to testing of HRQoL,lung function and exercise tolerance. 
3.5.1)Completion of the Physical Activity Readiness Questionnaire (Par-
Q): 
All participants who completed the demographic data sheet and the Par-Q and were found to 
be eligible were included into the study.  
3.5.2)Group allocation: 
Group allocation was performed after the participants had signed the informed consent sheet 
and the purpose of the study had been explained. The IPRA randomly allocated the 
participants into either the intervention or control groups by selecting a folded coloured piece 
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of paper from a box. Each colour represented either the control or intervention group into 
which the participant would be allocated. The participants that were allocated into either the 
intervention or control group were recorded and listed on a separate document kept by the 
IPRA.  
The IPRA marked each data capture sheet of the participants with the colour that was selected 
during the recruitment process that would separate the participants into the intervention 
group and the control group. The blinded primary researcher was responsible for the testing of 
each participant at the baseline reading through to the sixth week of testing.  
The procedures that were performed for the HRQoL, exercise tolerance and lung function 
assessments are outlined in detail below. 
3.5.3)Completion of Health Related Quality of Life Questionnaire 
Once the informed consent sheet and the demographic data had been completed, the IPRA 
and the participant were seated at a table with the questionnaire between them.  
The overview of the questionnaire including the reason why the questionnaire had to be 
completed, the type of questions that would be asked and the information that the 
questionnaire would require the participant to disclose was thoroughly explained to each 
participant. The questionnaire was made available in three different languages namely; 
English, Afrikaans and Xhosa. Most of the participants preferred the questionnaire in Xhosa.  
The duration for the completion of the questionnaire took approximately 8-10 minutes 
depending on the understanding of the participant with regard to the questions asked.  
The HRQoL was repeated at the 3rd and 6th week of the study for each individual participant at 
the follow-up appointments.  
3.5.4)Pulmonary Function: 
The procedure of the lung function testing was done in a well ventilated area within the clinic 
complex. The lung function testing of all the participants recruited into the study was 
performed using a spirometer, MINATO AUTOSPIRO- model AZ-505. The individual participants 
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were seated opposite the primary researcher with a table which contained the data capture 
sheet of the participant, the spirometer that would be used and a stopwatch.  
Firstly, the procedure of the lung function testing was explained to the participant before the 
researcher gave a demonstration of the necessary mechanics of the test. Disposable mouth 
pieces were used to ensure the hygiene of the test and the safety of the participants 
undergoing the lung function test. The participant practiced the mechanics of breathing in 
deeply and then forcibly expiring in the absence of the spirometer. Instruction to the 
participant when performing the test was to inhale deeply and exhale with as much force as 
possible into the mouthpiece keeping a tight seal around the mouthpiece with their lips. When 
the action was performed correctly, the participant repeated the procedure thrice with the 
spirometer. A nose-clip was utilized to ensure the participants did not exhale through the 
nose. Postural correction was performed in the sitting position to ensure maximum effort from 
the participant and the necessary safety precautions to protect the primary researcher. Once 
the lung function testing procedure was completed, the mouthpiece was taken off the 
spirometer and placed in a disposable bag which was disposed of at the end of each testing 
day at the CHC.The three readings of the lung function test were recorded and the mean 
calculated at a later stage.  
3.5.5)Exercise tolerance assessed by the 6-min walk test 
The exercise testing was performed after the procedure of the lung function testing. A break of 
5 minutes was allowed for rest while the procedure for the pre-exercise testing vitals was 
explained to the participant.  
Vitals taken by the primary researcher included resting Heart Rate (HR), resting Respiratory 
Rate (RR). Manual techniques assessing HR and RR were utilized before and after the exercise 
tolerance testing procedure. Resting HR was assessed by palpating the radial pulse, measuring 
the rate of the HR in 30 seconds and multiplying by two to obtain the HR in one minute. The 
resting RR was assessed by palpating the chest wall and measuring the number of breaths 
taken in one minute to obtain the resting RR. Once the resting HR and the resting RR were 
obtained, the exercise tolerance procedure was explained to the participant allowing a rest 
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period of five minutes to normalize the HR and RR before starting the exercise tolerance 
testing procedure. 
3.5.5i)Distance allocation: 
 A distance of 25 meters (m) marked off where the participants performed the walk test. A 
starting point had been clearly marked off along the walking path as well as a turnaround point 
where the 25m mark was placed. One circuit was counted as 50m, with the participants 
returning to the starting point. Yellow cones were used to mark where the participant would 
start the walk test and where the turnaround point was. In between the starting point and the 
25m mark, each 5m was marked with duct tape to indicate where the participants had 
stopped on the 50 m circuit once the six minutes had expired.  
3.5.5.2ii)Explanation of the procedure to the participant: 
The instruction to the participants at the starting point was to walk to the marker at the end of 
the track and back again as many times as possible in the six minutes allocated for the test. 
The participant was told that if at any stage s/he started feeling unwell, the test would be 
stopped immediately and medical advice would be sought in the trauma unit. The primary 
researcher was placed at the start of the walking circuit to record how many times the 
participant completed a 50m course in six minutes. Once the test had been started, the 
primary researcher gave continuous encouragement to the participant to keep walking the 
50m circuit and informed the participant how much time was left for the completion of the 
test.  
3.5.5iii)Recording of distance and vitals post exercise tolerance 
testing: 
While the participant was completing the exercise testing, the primary researcher kept a 
continuous count on the distance covered by the participant until the allocated time was 
finished. Once the allocated time for the exercise test was completed, the primary researcher 
was able to immediately seat the participant and take the post exercise HR and RR because the 
distance had been recorded while the participant had been walking. 
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The intensity of the walking segment of the exercise programme was to be calculated from 60-
75% of the reserve heart rate. When the concept was explained to the participants, many did 
not understand how to adjust their walking speed accordingly. Adjustments then had to be 
made to the explanation of the participant. Participants were then instructed to walk faster 
every day when doing the walking component of the exercise programme.  
3.5.5iv)Borg Scale Reading: 
The participants were given a resting period of two minutes to recover from the walking test 
to complete the Visual Analogue Scale using the 15-Grade Modified Borg Scale (Appendix J) to 
assess the difficulty of the exercise tolerance procedure. The participant chose a number 
which best suited their exertion level while performing the testing procedure. The grading was 
recorded on the data capture sheet and stored.  
3.9)Home Based Pulmonary Rehabilitation Programme: 
When all the baseline parameters where obtained and the participant had received adequate 
rest after the 6-min walk test, the participant went back to the IPRA for the home based PRP to 
be explained if they were included into the intervention group. If the participants were 
included into the control group, the information leaflet (Appendix K) was given to the 
participants with a follow-up date.  
The exercise programme was made available in English, Xhosa and Afrikaans. The English and 
Xhosa versions of the exercise programmes were most requested when the programmes were 
explained.  
The exercise programmes included a diagram of the exercises that needed to be completed as 
well as instructions on repetitions, sets and duration. The IPRA demonstrated the activity 
required of them and made sure the participants understood each exercise.  
3.9.1)Recording of daily activities: 
Attached to the exercise programme was a check list of the exercises that the participants had 
to complete on a daily basis. Once the participant had completed the exercise activity as 
stipulated on the handout given to the participants included into the intervention group, the 
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exercise was to be marked off for that particular day in the allocated section. The check list 
made provision for the two weeks that the participant was required to monitor and execute 
the exercise programme independently in the home environment. When the participant 
returned for follow-up appointments, the check-list was re-evaluated to see how the 
participant had progressed with the programme and if any problems had been encountered by 
the participant during the time that the exercise programme had to be done.  
3.10)Statistical analysis: 
The data was entered in Excel and analyzed in SPSS Version 10.1.3.Descriptive statistics were 
used to present the demographic information. The relationship between two different sets of 
data was analyzed using the following statistical techniques: 
The comparison of the baseline measurements and follow-up measurements of the exercise 
capacity and the lung function parameters were measured by using Wilcoxon signed-rank test 
for the duration of the six week period. Spearman’s rank correlation coefficients were 
calculated to assess the possibility of a relationship between exercise training and the HRQoL 
of the participant after the intervention period. Utility weights were assigned to each domain 
for the assessment of the HRQoL. Assessment of the Visual Analogue Scale (Modified Borg 
Scale) was assessed in the same manner as the HRQoL. The final data being normally 
distributed, an independent t-test was used to compare the HRQoL data of the intervention 
and the control groups. The Mann Whitney U Test was used to assess the final data of the 
HRQoL if it was not normally distributed for comparison of the two groups. Level of 
significance was set at p<0.05 for all the tests that were performed.  
3.11)Ethical considerations: 
Ethical approval(Appendix L) from the Faculty of Health Sciences, Research Ethics Committee 
of the University of Cape Town was obtained prior to the commencement of the study. 
Permission from the Ubuntu Clinic as well as the City Health Council was also obtained. All 
information obtained from the data capture sheet and the demographic questionnaire was 
stored in a secure place so that no one other than the research team was able to view the 
information obtained. All information obtained was treated with the strictest confidentiality. 
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To ensure anonymity, a coding system was implemented by administering each participant 
with a number which correlated to the baseline and follow-up information.     
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CHAPTER 4: 
RESULTS 
4.1)Introduction 
The data collected was analyzed using SPSS version 18 which included the demographic data, 
HRQoL Questionnaire, Lung function parameters, exercise tolerance and Borg Scale. Stata 
(Version 11.1) was used to perform further statistical analysis (Refer to chapter 3) . The results 
will be reported in two main sections (a) description of the demographics of the total sample 
and (b) differences of the control and intervention groups with regard to HRQoL, pulmonary 
function and exercise tolerance. The data will be displayed using tables and graph. Baseline 
readings will be compared to the findings of the sixth week only with regard to HRQoL, lung 
function and exercise tolerance.The total number of patients recruited was 102. Of the total 
number of patients recruited (n=102) only 67 patients remained for the completion of the six 
week exercise programme. Five patients were transferred to secondary hospitals and inpatient 
facilities to have further investigation done. Nine patients were recruited into the study but 
did not return due to being admitted to other CHC’s that were more accessible to their new 
place of residency. Three patients discontinued the exercise programme due to a difficult time 
schedule with regards to time constraints in travelling to the clinic and then to work. Eight 
patients did not complete the six week exercise programme due to personal problems and 
relocation to the Eastern Cape. Ten participants did not return and were unable to be reached 
telephonically to provide a valid reason for their disappearance. Thus the total sample that 
completed the study was 67 participants. See Consort flow chart (fig 4.1) 
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Lost to follow-up (n= 1) 
 Did not keep follow-up appointments and 
could not be telephonically contacted 
Discontinued intervention (n=16) 
 Admitted to other CHC’s because of 
accessibility 
 Transferred for follow-up management at 
a secondary hospital 
 Time constraints 
Personal problems 
 
 
 
Analysed  (n=34) 
Excluded from analysis (n=0) 
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4.2)Demographics: 
The profile of the participants recruited into the study is tabulated below (Table 4.1) providing 
information about gender, occupation, educational status, marital status, smoking history, 
diagnosis of the participants, whether the participants were on Anti-Retroviral (ARV) 
treatment and the type of PTB treatment regimen the participants were currently on.  
Table 4.1: Demographic data of study participants 
  Total sample group (n=67) Control Group 
(n=33) 
Intervention Group 
(n=34) 
Gender Male 33 (49%) 16 (49%) 17 (50%) 
Female 34 (51%) 17 (51%) 17 (50%) 
Occupation Employed 17 (25%) 7 (21%) 10 (29%) 
Unemployed 50 (75%) 26 (79%) 24 (71%) 
Level of Education No formal Education 0 0 0 
Primary School  
(Gr. 1-7) 
16 (24%) 11 (33%) 5 (15%) 
High School  
(Gr. 8-11) 
36 (54%) 17 (52%) 19 (56%) 
Completed Gr. 12 15 (22%) 5 (15%) 10 (29%) 
Marital status Married  22 (33%) 11 (33%) 11 (32%) 
Widowed 2 (3%) 0 (0%) 2 (6%) 
Divorced/single 43 (64%) 22 (67%) 21 (62%) 
Smoking History    Current smoker 5 (7%) 4 (12%) 1 (3%) 
Ex-smoker 29 (43%) 15 (46%) 14 (41%) 
Never smokedbefore 33 (49%) 14 (42%) 19 (56%) 
Diagnosis PTB only
1 
21 (31%) 10 (30%) 11 (32%) 
PTB + HIV
2 
46 (69%) 23 (70%) 23 (68%) 
ARV'S
3 
Yes 45 (67%) 22 (67%) 23 (68%) 
 No 22 (33%) 11 (33%) 11 (32%) 
PTB regimen
4 
1 23 (34%) 14 (42%) 9 (26%) 
 2 44 (66%) 19 (58%) 25 (74%) 
 
 
1
Pulmonary Tuberculosis (PTB) is an infectious lung disease acquired by the inhalation of air borne particles 
spread by coughing and sneezing. 
2
Human Immunodeficiency Virus (HIV) with the co-infection of PTB 
3
Anti-retroviral treatment (ARV’s) is the medication that patients diagnosed with HIV are placed on to maintain an   
optimal level of the CD4 count. 
4
Patients who have a primary diagnosis of PTB are administered with PTB regimen 1 medication. Patients who do 
not respond to treatment are prescribed different medication  
 
Allocation 
Follow-up 
Lost to follow-up (n=9) 
 Did not keep follow-up appointments and 
could not be telephonically contacted 
Discontinued intervention (n=9) 
 Admitted to other CHC’s because of 
accessibility 
 Transferred for follow-up management at 
a secondary hospital 
 
Allocated to control (n=51) 
Received baseline assessment (n=51) 
Did not receive allocated intervention (n=0) 
Allocated to intervention (n=51) 
Received allocated intervention (n=51) 
Did not receive allocated intervention (n=0) 
Analysis 
Analysed  (n=33) 
Excluded from analysis (n=0) 
Enrollment 
Randomized (n=102) 
Excluded (n=28) 
Not meeting inclusion criteria (n=0) 
Declined to participate (n=28) 
 Other reasons (n=0) 
Assessed for eligibility (n=130) 
Fig: 4.1 Consort Flow 
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With regard to gender the total sample size had minimal difference between male (n=33) and 
females participants (n=34). Nearly 75% of the participants were unemployed with less than 
25% of them having completed their formal education. Almost a quarter (24%) of the total 
population size had only completed their primary school level education while 54% dropped 
out of school before matriculating. A third (31%) of the participants were diagnosed as having 
PTB in the absence of HIV as a co-morbidity. Of the remaining participants who were 
diagnosed with PTB and HIV, all but one participant was receiving ARV treatment. The majority 
of patients (66%) in the study received PTB regimen 2 which is associated with Multi-Drug 
Resistant PTB (MDR-TB). 
When comparing the demographic data of the control and intervention groups, there were 
similarities in all the categories except that of the type of PTB regimen with the intervention 
group having a higher percentage (74%) of regimen 2 (Fig 4.2). Although this finding was not  
statistically significant (p> 0.05), it is of clinical significance.  
 
Fig 4.2: Comparison of the PTB regimen in the intervention and control groups. 
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4.3)Health Related Quality of Life (HRQoL) 
In this section, HRQoL will be reported in the following sequence:HRQoL of all the participants 
in the total sample size, HRQoL of PTB-only diagnosed participants in the control and 
intervention groups, HRQoL of participants with the co-infection of HIV in the control and 
intervention groups, HRQoL of participants pertaining to PTB regimen. 
4.3.1)HRQoL of all participants 
A decrease in the domains of mobility, self-care and activities and an improvement in pain, 
anxiety and VAS were seen in the control and intervention groups (Refer table 4.2). In the sixth 
week of testing, the ability to perform activities was easier in the control group (15.10%) 
compared to the intervention group (19.25%). The intervention group however showed a 
greater percentage improvement from baseline to the sixth week in the domains of pain 
(20.56 %), anxiety (14.49 %) and VAS% (20.6 %) when compared to the control group.  
Table 4.2: HRQoL in relation to the control and intervention groups 
 Control group (n=33) Intervention group (n=34) 
 Mean Range Std.Dev Mean Range Std.Dev 
Mobility 1.48 1-2 0.51 1.44 1-2 0.50 
Self-care 1.18 1-2 0.39 1.18 1-2 0.39 
 Activities 1.39 1-3 0.56 1.35 1-2 0.49 
Pain 1.52 1-2 0.51 1.41 1-2 0.50 
Anxiety 1.45 1-2 0.51 1.38 1-3 0.60 
VAS% 84.24 50-100 13.47 79.26 30-100 18.51 
EQ-5D WEEK 6 
Mobility 1.15 1-2 0.36 1.15 1-2 0.36 
Self-care 1.03 1-2 0.17 1.03 1-2 0.17 
Usual Activities 1.18 1-3 0.47 1.09 1-2 0.29 
Pain/discomfort 1.21 1-2 0.42 1.12 1-2 0.33 
Anxiety/depression 1.24 1-3 0.56 1.18 1-3 0.46 
VAS% 94.24 60-100 8.30 95.59 70-100 6.83 
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The level of education as assessed in the EQ-5D found that the intervention group had a higher 
number of participants with formal education after the minimum school leaving Grade 7 
(n=22). The intervention group also had more participants with a degree or diploma (n=3). The 
aforementioned difference was statistically significant (p<0.03). 
The frequency of participants experiencing problems and no problems in the respective 
domains is presented in Table 4.3. The frequency of reported problems as measured by the 
EQ-5D indicated minimal changes between the intervention and control groups and was not 
statistically significant for the domains of mobility, self-care, activities, pain and anxiety 
(p>0.05) at the sixth week of testing. 
Table4.3: Frequency of reported problems in the Intervention and Control Groups 
 Intervention Group Control Group 
EQ-5D Domains Baseline Week 6 Baseline Week 6 
Mobility No Problems 19 29 17 28 
Problems 15 5 16 5 
Self-care No Problems 28 33 27 32 
Problems 6 1 6 1 
Usual 
Activities 
No Problems 22 31 11 28 
Problems 12 3 12 5 
Pain No Problems 20 30 16 26 
Problems 14 4 17 7 
Anxiety No Problems 23 29 18 27 
Problems 11 5 15 6 
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4.3.2)Health Related Quality of Life in relation to the diagnosis of PTB-only 
A third of the participants (30%) in the control group were diagnosed with PTB-only and the 
intervention group had a similar proportion (32%). Both the control and intervention groups 
showed similar changes in the domain of mobility (23.9% vs. 20%). The intervention group 
showed further improvements in the domains of self-care (15.30% vs. 9.1%) and activities 
(14.20% vs. 8.30%) while the control group however showed improvements in the domains of 
pain (20% vs. 13.2%) and anxiety (16.7% vs. 0%) at the end of the sixth week.  
Table 4.4: HRQoL in relation to the diagnosis of PTB-only 
 Control group PTB-only (n=10) Intervention group PTB-only (n=11) 
Diagnosis Mean5 Range Std. Dev Mean Range Std. Dev 
Mobility 1.50 1-2 0.53 1.55 1-2 0.52 
Self-care 1.10 1-2 0.32 1.18 1-2 0.41 
Activities 1.20 1-2 0.42 1.27 1-2 0.47 
Pain 1.50 1-2 0.53 1.36 1-2 0.51 
Anxiety 1.20 1-2 0.42 1.18 1-2 0.41 
Vas%6 85.00 50-100 15.81 84.09 45-100 12.08 
Week 6 
Mobility 1.20 1-2 0.42 1.18 1-2 0.41 
Self-care 1.10 1-2 0.32 1.00 1-1 0.00 
Activities 1.30 1-3 0.68 1.09 1-2 0.30 
Pain 1.20 1-2 0.42 1.18 1-2 0.41 
Anxiety 1.00 1-2 0.00 1.18 1-2 0.41 
Vas% 90.50 60-100 12.57 95.45 80-100 6.87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
Mean was calculated to show a decrease or improvement in each domain the control and intervention groups 
respectively 
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6Visual Analogue Scale (VAS) is a subjective measure to assess how the participant feels about 
their health on that particular day 
 4.3.3)Health Related Quality of Life in relation to PTB/HIV diagnosis 
Participants in the control group (34%) and intervention groups (34%) diagnosed with PTB/HIV 
had similar increases in the domains through the six week period. Although not statistically 
significant (p>0.05), the intervention group improved the most in the domain of VAS during 
the sixth week (24.29% vs. 14.30%). The control group however, experienced improvements in 
the domains of mobility (23.60%) and self-care (18.00%) (Table 4.5.). 
Table 4.5: Health Related Quality of Life in relation to PTB/HIV diagnosis 
 Control group PTB/HIV (n=23) Intervention group PTB/HIV (n=23) 
Diagnosis Mean Range Std. Dev Mean Range Std. Dev 
Mobility 1.48 1-2 0.51 1.39 1-2 0.50 
Self-care 1.22 1-2 0.42 1.17 1-2 0.39 
Activities 1.48 1-3 0.59 1.39 1-2 0.50 
Pain 1.52 1-3 0.51 1.43 1-2 0.51 
Anxiety 1.57 1-2 0.51 1.48 1-3 0.67 
Vas% 83.91 50-100 12.70 76.96 30-100 18.20 
Week 6 
Mobility 1.13 1-2 0.34 1.13 1-2 0.34 
Self-care 1.00 1-1 0.00 1.04 1-2 0.21 
Activities 1.13 1-2 0.34 1.09 1-2 0.29 
Pain 1.22 1-2 0.42 1.09 1-2 0.29 
Anxiety 1.35 1-3 0.65 1.17 1-3 0.49 
Vas% 95.87 85-100 5.15 95.65 70-100 6.96 
 
4.3.4)Health Related Quality of Life in relation to PTB regimen 1 
The control and intervention groups were further divided into participants undergoing PTB 
treatment regimen 1 and 2. This paragraph reports on the information obtained from 
participants in treatment regimen 1 (Table 4.6). The control group had more participants 
undergoing PTB regimen 1 treatment (42%) than the intervention group (26%). After the sixth 
week testing, the intervention group dramatically increased in the domain of mobility (87.64%), 
activities (22.92%), as well as the VAS (22.30%). 
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Table 4.6: Health Related Quality of Life in relation to PTB regimen 1 
 Control group Regimen 1(n=14) Intervention group Regimen 1(n=9) 
Diagnosis Mean Range Std. Dev Mean Range Std.Dev 
Mobility 1.50 1-2 0.52 1.78 1-2 0.44 
Self-care 1.07 1-2 0.27 1.11 1-2 0.33 
Activities 1.14 1-2 0.36 1.44 1-2 0.53 
Pain 1.29 1-2 0.47 1.56 1-2 0.53 
Anxiety 1.57 1-2 0.51 1.56 1-3 0.73 
Vas% 91.43 70-100 9.49 77.22 45-100 18.89 
Week 6 
Mobility 1.14 1-2 0.36 1.22 1-2 0.44 
Self-care 1.07 1-2 0.27 1.00 1-1 0.00 
Activities 1.21 1-3 0.58 1.11 1-2 0.33 
Pain 1.14 1-2 0.36 1.22 1-2 0.44 
Anxiety 1.00 1-2 0.00 1.11 1-2 0.33 
Vas% 92.50 60-100 11.22 94.44 80-100 7.27 
 
4.3.5)Health Related Quality of Life in relation to PTB treatment 
regimen 2 
A large percentage of participants in the intervention group (74%) were undergoing PTB 
treatment regimen 2. The intervention group had no significant improvement in any of the 
domains after the six week period although the control group did show a slightly higher degree 
of improvement in the domains of mobility (21.09%), self-care (20.64%) and activities (26.58%) 
after the sixth week (Table 4.7). Other than the minimal improvement of the control group in 
the domain of anxiety (4.40%), comparison between the values of the control and intervention 
groups for each domain were similar.  
Table 4.7: Health Related Quality of Life in relation to PTB treatment regimen 2 
 Control group PTB treatment Regimen 2 
(n=19) 
 
Intervention group PTB treatment 
Regimen 2 (n=25) 
Diagnosis Mean Range Std.Dev Mean Range Std.Dev 
Mobility 1.47 1-2 0.51 1.32 1-2 0.48 
Self-care 1.26 1-2 0.45 1.20 1-2 0.41 
Activities 1.58 1-3 0.61 1.32 1-2 0.48 
Pain 1.68 1-2 0.48 1.36 1-2 0.49 
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Anxiety 1.37 1-2 0.50 1.32 1-3 0.56 
Vas% 78.95 50-100 13.90 80.00 30-100 18.71 
Week 6 
Mobility 1.16 1-2 0.38 1.12 1-2 0.33 
Self-care 1.00 1-1 0.00 1.04 1-2 0.20 
Activities 1.16 1-2 0.38 1.08 1-2 0.28 
Pain 1.26 1-2 0.45 1.08 1-2 0.28 
Anxiety 1.43 1-3 0.69 1.20 1-3 0.50 
Vas% 95.53 85-100 5.24 96.00 70-100 6.77 
 
4.4) Lung Function: 
The lung function of the participants in the control and intervention groups were measured by 
assessing the parameters of Forced Expiratory Volume in one second (FEV1), Forced Vital 
Capacity (FVC) and the ratio of FEV1/FVC (Refer to Table 4.8). At the end of the sixth week of 
testing, the value of FEV1 was statistically significant (p<0.02) for the intervention group. 
Continued improvements in the intervention group were noted from baseline testing to the 
sixth week with regard to the lung parameters of FEV1 (10.63%) and FVC (10.71%). The control 
group however had lower readings in the aforementioned parameters of FEV1 and FVC after 
the sixth week of testing in comparison to the intervention group(Table 4.8). 
Table 4.8: Lung function readings of the control and intervention group 
 Control group (n=33) Intervention group (n=34) 
 Mean Range Std.Dev Mean Range Std.Dev 
FEV1 (L) 1.47 0.50-4.15 0.70 1.60 0.82-3.11 0.56 
FVC (L) 1.54 0.53-4.19 0.71 1.68 0.94-3.32  0.57 
FEV1/FVC 0.95 0.72-1.00 0.07 0.96 0.77-1.00 0.06 
Week 6 
FEV1 (L) 1.54 0.45-4.10 0.66 1.77 1.07-2.99 0.54 
FVC (L) 1.64 0.54-4.12 0.68 1.86 1.07-3.30 0.58 
FEV1/FVC  0.94 0.64-1.00 0.07 0.96 0.79-1.00 0.06 
 
4.4.1)Lung function parameters according to the diagnosis of PTB-only 
From the table below (table 4.9), which represents the PTB-only subgroup within the 
intervention and control groups, a greater improvement was seen in the intervention group 
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after the six week testing. At the end of the sixth week of testing, the intervention group 
continued to improve in the values of FEV1 (18.60%) and FVC (22.20%) while the control group 
experienced a decrease in lung parameter values.  
Table 4.9: Lung function readings of PTB-only participants 
  Control group PTB-only (n=10) Intervention group PTB-only (n=11) 
Parameters Mean Range Std.Dev Mean Range Std.Dev 
FEV1 1.49 0.87-2.24 0.50 1.67 0.87-3.11 0.66 
FVC 1.60 0.89-2.53 0.57 1.71 0.94-3.32 0.70 
FEV1/FVC 0.94 0.78-1.00 0.75 0.98 0.93-1.00 0.03 
Week 6 
FEV1 1.28 0.45-2.41 0.62 1.98 1.23-2.95 0.65 
FVC 1.39 0.54-2.42  0.62 2.09  1.25-3.17  0.69  
FEV1/FVC 0.91 0.64-1.00 0.11 0.95 0.79-1.00 0.08 
 
4.4.2) Lung function parameters of PTB/HIV participants 
Minimal improvement was seen in the intervention group in the values of (FEV1, 10.70%;FVC, 
9.5%) and the control group (FEV1, 13.00%; FVC, 15.90%) after the sixth week of testing (table 
4.10). 
Table 4.10: Lung function parameters of PTB/HIV participants 
  Control group PTB/HIV (n=23) Intervention group PTB/HIV (n=23) 
Parameters Mean Range Std.Dev Mean Range Std.Dev 
FEV1 1.46 0.50-4.15 0.78 1.50 0.82-2.93 0.51 
FVC 1.51  0.53-4.19  0.78 1.58 1.02-3.03 0.51 
FEV1/FVC 0.96 0.72-1.00 0.07 0.95 0.77-1.00 0.07 
Week 6 
FEV1 1.65 0.93-4.10 0.65 1.66 1.07-2.99 0.45 
FVC 1.75  0.96-4.12  0.68 1.73 1.07-3.30 0.48 
FEV1/FVC 0.95 0.80-0.99 0.04 0.96 0.87-1.00 0.04 
 
4.4.3)Lung function Parameters in participants undergoing PTB 
treatment Regimen 1 
The percentage of participants undergoing PTB treatment regimen 1 were less in the 
intervention group (13%) in comparison to the control group (21%). The readings in the 
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intervention group for FEV1 (25.97%) and FVC (31.84%) (Fig 4.16) for this subgroup showed a 
greater improvement, although not statistically significant (p>0.05), at completion of the sixth 
week when compared to the control group (Table 4.11).  
Table 4.11: Lung Parameters in participants undergoing PTB treatment Regimen 1 
  Control group PTB treatment Regimen 
1 (n=14) 
Intervention group PTB treatment 
Regimen 1(n=9) 
Parameters Mean Range Std.Dev Mean Range Std.Dev 
FEV1 1.67 0.83-4.15 0.85 1.54 0.87-2.23 0.48 
FVC 1.73 0.83-4.19 0.88 1.57 0.94-2.27 0.47 
FEV1/FVC 0.97 0.86-1.00 0.05 0.98 0.93-1.00 0.02 
Week 6 
FEV1 1.39 0.45-2.41 0.58 1.94 1.23-2.95 0.70 
FVC 1.53 0.54-2.78 0.64 2.07 1.25-3.17 0.76 
FEV1/FVC 0.91 0.64-1.00 0.10 0.94 0.79-1.00 0.08 
 
4.4.4)Lung function parameters of participants undergoing PTB 
treatment regimen 2 
More than a third (37%) of the participants in the intervention group was undergoing PTB 
treatment regimen 2 compared to the control group (28%) (Table 4.12). The intervention 
group showed slight improvements in the parameters of FEV1 (4.27%) and FVC (12.82%) from 
baseline to the sixth week of testing. Although the control group had a greater improvement in 
the parameters of FEV1 (25%) and FVC (22.86%), they were not statistically significant (P>0.05). 
Table 4.12: Lung function testing of participants undergoing PTB treatment regimen 2 
  Control group PTB Regimen 2 (n=19) Intervention group PTB Regimen 2 
(n=25) 
Parameters Mean Range Std.Dev Mean Range Std.Dev 
FEV1 1.32 0.50-2.48 0.55 1.56 0.82-3.11 0.59 
FVC 1.40 0.53-2.49 0.54 1.64 1.02-3.32 0.61 
FEV1/FVC 0.94 0.72-1.00 0.09 0.95 0.77-1.00 0.07 
Week 6 
FEV1 1.65 0.93-4.10 0.70 1.76
7 1.07-2.99 0.47 
FVC 1.72 0.96-4.12 0.71 1.71 1.07-3.30 0.49 
FEV1/FVC 0.95 0.89-0.99 0.03 0.97 0.87-1.00 0.04 
7
Statistically significant value of FEV1 (p<0.02) 
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4.5)Exercise Toleranceand Borg Scale reading 
The physical ability of the participants recruited into the study as well as the rate of perceived 
exertion, measured by a Modified Borg Scale (table 4.13) provides information with regard to 
the distance covered by the participants and the perceived difficulty of the exercise tolerance 
test after completion.  
The difference of the distance covered by the intervention and control group had statistical 
significance (p<0.02) at the baseline reading but the improvement of the control group and 
intervention group at the end of the sixth week was not statistically significant (p>0.7). After 
the sixth week of testing, the intervention had covered a greater mean distance (411.03m) 
although the control group had a higher percentage improvement from baseline to the sixth 
week of testing (Table 4.13). The intervention group had a lower reading of the Borg Scale 
(10.35) indicating a better perceived exertion of the exercise tolerance test in comparison to 
the control group (11.24) at the sixth week of testing. 
Table 4.13: Exercise tolerance and Borg scale reading for the Intervention and Control group 
 
 
Control Group (n=33) Intervention group (n=34) 
 Mean Range Std.Dev Mean Range  Std.Dev 
Distance 
(m) 
340.00 160-680 104.67 401.18 200-600 96.13 
Borg Scale 
reading 
11.42 7-15 1.64 10.06 7-15 2.32 
WEEK 6 
Distance 
(m) 
356.97 190-520 78.72 411.03 235-580 79.79 
Borg Scale 
reading 
11.24 
 
7-15 1.48 10.35 
 
7-13 1.82 
 
4.5.1)Exercise tolerance and Borg Scale reading of participants diagnosed with PTB-
only 
PTB-only diagnosed participants in the intervention group were able to cover a greater mean 
distance (445.45m)  than the control group (322m) at the baseline measurement (Refer to 
Table 4.14) although after the sixth week of testing the intervention group decreased in the 
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mean distance covered (442.73m) while the control group improved (367.00m). Although the 
intervention group PTB-only participants had a lower Borg scale (10.27) compared to the 
control group (11.60) reading at baseline, the intervention group continued to show greater 
improvements after the sixth week testing. 
Table 4.14: Distance of the participants diagnosed with PTB-only 
 Control PTB-only (n=10)  Intervention PTB-only (n=11) 
Parameters Mean Range Std. Dev Mean Range Std. Dev 
Distance(m) 322.00 200-450 96.47 445.45 330-550 65.17 
Borg scale 11.60 7-15 2.12 10.27 7-13 2.24 
Week 6 
Distance(m) 367.00 280-500 73.64 442.73 330-580 71.29 
Borg scale 11.00 7-13 1.63 9.55 7-11 2.02 
 
4.5.2)Exercise tolerance and Borg Scale reading of participants diagnosed with 
PTB/HIV 
Both the intervention and control groups had the same number of participants diagnosed with 
PTB/HIV (n=23). Covering a greater distance at baseline (380m), the intervention group had a 
greater improvement ( 395.87m) in the sixth week of testing compared to the control group 
(352.61) (Table 4.15). With the Intervention group increasing the value of the Borg Scale 
reading from baseline (9.96) to the sixth week (10.74), the control group showed no change 
from baseline (11.35) to the sixth week (11.35).  
Table 4.15: Distance covered by participants diagnosed with PTB/HIV 
 Control PTB/HIV (n=23)  Intervention PTB/HIV (n=23) 
Parameters Mean Range Std. Dev Mean Range Std. Dev 
Distance (m) 347.83 160-680 109.17 380.00 200-600 102.38 
Borg scale 11.35 7-15 1.43 9.96 7-15 2.40 
Week 6 
Distance (m) 352.61 190-520 82.03 395.87 235-500 80.60 
Borg scale 11.35 7-15 1.43 10.74 7-13 1.63 
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4.5.3)Exercise tolerance and Borg Scale reading of participants undergoing PTB 
treatment regimen 1 
Although the intervention group had covered a greater distance at baseline (426.67) in 
comparison to the control group (372.14), similar trends were seen in both groups with 
regards to a decrease in the distance covered after the sixth week testing (Refer to table 4.16). 
Similarly, in the Borg Scale reading, the intervention group had a lower reading (9.67) than the 
control group (11.29) and continued to show a greater improvement in the Borg scale reading 
after the sixth week (9.22). 
Table 4.16: Distance and Borg Scale of participants undergoing PTB treatment regimen 1 
 Control PTB Regimen 1 (n=14)  Intervention PTB Regimen 1 (n=9) 
Parameters Mean Range Std. Dev Mean Range Std. Dev 
Distance (m) 372.14 200-680 128.55 426.67 340-550 63.84 
Borg scale 11.29 7-15 1.72 9.67 7-13 2.65 
Week 6 
Distance (m) 369.29 240-500 76.71 438.89 330-580 78.97 
Borg scale 11.00 7-15 2.08 9.22 7-11 2.11 
 
4.5.4)Exercise tolerance and Borg Scale reading of participants undergoing PTB 
treatment regimen 2 
Minimal improvement was achieved with the intervention group with regards to the distance 
covered from baseline (392m) to the sixth week of testing (401m) whereas the control group 
had a greater improvement in the sixth week (347.89m) (Table 4.17). Although the Borg Scale 
reading for the intervention group had increased from baseline (10.20) to the sixth week 
(10.76), the reading was still lower than that of the control group in the sixth week (11.42). 
Table 4.17: Distance and Borg Scale of participants undergoing PTB treatment regimen 2 
 Control group PTB Regimen 2 (n=19)  Intervention group PTB Regimen 2 
(n=25) 
 MEAN RANGE STD.DEV MEAN RANGE STD.DEV 
Distance (m) 316.32 160-470 78.40 392.00 200-600 104.96 
Borg scale 11.53 7-15 1.61 10.20 7-15 2.24 
Week 6 
Distance (m) 347.89 190-520 81.01 401.00 235-500 79.24 
Borg scale 11.42 11-13 0.84 10.76 7-13 1.56 
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4.6) Conclusion 
Similar changes were seen in the intervention and the control groups over the six week period. 
Although not statistically significant, clinical improvement was greater in the HRQoL of the 
intervention group. HRQoL domains included anxiety and pain in which the intervention group 
had a greater improvement over the six week period. At the end of the sixth week, the reading 
for FEV1 was statistically significant (p>0.02) in the intervention group. 
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CHAPTER 5: 
DISCUSSION 
5.1)Introduction 
Pulmonary Tuberculosis (PTB) still poses a major health challenge in South Africa. The reality of 
the current PTB epidemic internationally and nationally is overwhelming and often 
demoralizing to the health professionals assisting in the management process of the patients 
diagnosed with PTB. The situation is worsened by the co-infection of almost half the 
population infected with PTB and HIV as these patients suffer greater morbidities (Loveday et 
al, 2007). Evidence, in the literature, has identified strategies to address the occurrence and 
impact that the disease has on the population. However, long term management of patients 
with PTB has not been adequately addressed, especially when the patients are discharged 
from hospitals back into their homes and communities. The aforementioned are possible 
contributing factors as to why the Millennium Development Goals (MDGs) of eradicating PTB 
by 2015 may not be achievable (SA Department of Health, 2007-2011). This study was 
therefore developed to determine the effect of a home based pulmonary rehabilitation 
programme on HRQoL, lung function and exercise tolerance among patients with PTB. This six 
week programme included breathing exercises, walking in the community as well as 
strengthening exercises for both the upper and lower limbs. 
5.2)Profile of Participants 
The characteristics of the participants were similar to information obtained in current 
literature (PortwigandCouper, 2006; Loveday et al, 2007; Kourbatova et al; 2006). The level of 
unemployment and incomplete formal education in the total population of the current study 
participants were also consistent with literature. Participants were mostly unemployed (n=50) 
with a high number of participants havingincomplete high school education (n=52). Formal 
education not only  plays a major role in providing the correct thinking processes to cope with 
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everyday situations, it also provides the means to process information, as in the case of the 
current study, the disease process in the diagnosis of PTB . Education to newly diagnosed and 
previously diagnosed patients has fallen to the medical staff with fewer individuals being 
informed by television and public radio (Mesfin et al, 2005). Loss of patients in the health care 
system could thus result in patients not receiving treatment resulting in the increased 
morbidity and mortality experienced (Loveday et al, 2007). 
 The statistical value of education between the intervention and control groups in the current 
study was significant (p<0.03). The assessment of current support strategies for patients with 
PTB in Kwazulu-Natal conducted by Lutge et al (2009) found that there was a statistical 
significance between the educational level and the non-adherence of patients to the 
prescribed medication (p=0.039). Participants who had no formal education were more likely 
to default off the treatment, followed by those with primary and then secondary 
education(Lutge et al, 2009). The view that the higher literacy level of individuals will result in 
better compliance to medication compared to lower literate individuals is supported by 
Kalichman (1999).  
Factors affecting non-adherence in PTB diagnosed patients’ have been evaluated by many 
authors (Liam et al, 1999; Ukpe, 2007; Balbay et al, 2005; PortwigandCouper, 2006). The high 
degree of non-adherence, specifically to PTB medication, is evident in the current study where 
a total of 66% of the total population were currently on PTB treatment regimen 2 which is 
associated with multi-drug resistant PTB (MDR-TB). Ukpe (2007) supports this view in stating 
that by defaulting off the prescribed medication, ineffective management of PTB is 
experienced and adds extra strain to the already over burdened TB control programmes. 
The community, from which the participants for this study were selected, is reported to have a 
high prevalence of co-infection of PTB and HIV individuals (MSF TB Report, 2009). This in itself 
poses a challenge in the management of the patients due to the added morbidity associated 
with the HIV disease. For a long time, a great degree of stigma has surrounded the diagnosis of 
PTB as it is associated with the co-infection of HIV. According to Loveday et al (2007) this 
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stigmatization plays a significant role in non-adherence to PTB medication which results in 
further morbidity and even eventual mortality.  
5.3)Health Related Quality of Life 
Historically management of PTB patients has focused on the microbiological cure of the 
disease. In the last decade the focus has shifted to incorporate the measurement of HRQoL in 
the management of morbidity in patients suffering from PTB (Chamla, 2004; WHOQOL Group, 
1995). Although the total sample size did not show marked improvements in all the domains 
within the EQ-5D over the six week period, the sub-groups of PTB/HIV and PTB regimen 1 in 
the intervention group, showed the greatest clinical improvements in the domains of pain and 
anxiety respectively. The sub-group of participants diagnosed with PTB/HIV in the intervention 
group, experienced a decrease of 23.80% in the domain of pain after the six week period. With 
the decrease of pain in patients with the PTB/HIV diagnosis, the resultant relief could address 
the joint and muscular pain (Larue et al, 1997) that plays a part in the limitation of functional 
movement and the execution of activities of daily living (McCormack et al, 1993). Limitation in 
functional movement and the execution of activities of daily living could translate to the non-
compliance of clinical appointments due to the physical inability to get to the health care 
facility (Loveday et al, 2007).  Pain according to Holzemer (1998) is the main contributor to the 
decrease in the Quality of Life (QoL) in patients diagnosed with HIV/AIDS. As supported by 
Ghosh et al (2006), the incorporation of a rehabilitation programme for patients with co-
infection is not only needed to address morbidities but to improve the HRQoL of patients 
diagnosed with PTB (Ciccolo et al, 2004).  
Participants undergoing PTB regimen 1 in the intervention group showed a clinical 
improvement of 28.85% in the HRQoL domain of anxiety. Although HRQoL is often marginally 
improved after treatment (Chamla, 2004) patients with the diagnosis of PTB suffer from poor 
emotional quality of life even after microbiological cure (Rajeswari et al, 2005; Dhingra 
andRajpal, 2003). The seriousness of the anxiety experienced by the patient diagnosed with 
PTB has been largely overlooked (Husain et al, 2008) with the subsequent effect of poor 
compliance to PTB medication and decreased HRQoL. It has become evident thus that the 
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microbiological cure of PTB is no longer sufficient to ensure the overall well-being of the 
patient after treatment (Rajeswari et al, 2005). The informationobtained in the current study is 
vital in defining the role that physiotherapy can play in the management of patients with PTB. 
The concept of rehabilitation should no longer only extend to the physical management of 
patients but be inclusive of the emotional management of patients especially the long term 
care of PTB patients. 
5.4)Lung Function 
Even after microbiological cure at the end of the pharmaceutical management, lung function 
impairment as a result of the PTB diagnosis has been described as a long term disability which 
not only has a negative impact on the socio-economic status of the individual (Portwig 
andCouper, 2006) but has even greater limitation in the execution of functional activities on a 
daily basis (Maguire et al, 2009). 
While literature reflects that  improvement in lung function may be attributed to the effect of 
the medication as illustrated by Plit et al (1998), the current study found a statistically 
significant improvement (p<0.02) in the reading of FEV1 in the intervention group over the  six 
week period. This particular finding is  important to the management of PTB patients because 
according to the findings of Ghosh et al (2006), PTB patients were still symptomatic after 
completion of the prescribed PTB medication with an even greater degree of radiological 
abnormalities after treatment. The findings of the current study however were supported by 
Tada et al (2002) who found that pulmonary rehabilitation resulted in significant 
improvements of lung function in patients with PTB sequelae. This justifies the need identified 
by Ghosh et al (2006) for the inclusion of physiotherapy management of PTB patients, to 
address the increasing morbidity associated with the disease.Taking into account the 
magnitude of PTB , individual management of each patient diagnosed with PTB could be 
difficult, therefore the current study aimed to rehabilitate individuals in the community and 
the home environment. 
Furthermore the subgroup of PTB/Regimen 1 within the intervention group also reflected 
improvements in FEV1 (25.97%) and FVC (31.84%) albeit not statistically significant (p>0.05). A 
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plausible reason for the clinical improvement noted in this sub-group could be attributed to 
the early case detection (Kourbatova et al ; 2006) of untreated PTB because delays inPTB 
diagnosis have been linked to the severity of pulmonary impairment, the increased number of 
co-morbidities, as well as the negative impact on the well-being of the patient (Yaksic et al, 
2003). Al-Hajjaj (2002) identified treatment compliance to the medication as a factor that may 
affect the lung function after treatment which De Valliere and Barker (2004) supported by 
stating that individuals who have previously defaulted off first line drug treatment 
subsequently have a greater degree of lung function impairment. Thus the sub-group of PTB 
treatment regimen 1 individuals showed the greatest percentage of improvement in the lung 
parameters assessed. By assessing the results found in the study, the role of physiotherapists 
in the management of PTB patients leans not only to rehabilitation of the pulmonary 
morbidities experienced in these patients but providing the information and education for self-
management. 
5.5)Exercise Tolerance and Borg Scale Reading 
As a result of the impaired ability to maintain effective gaseous exchange patients experience 
an inability to perform activities of daily living (Sivaranjini andVanamail, 2010). 
In the total sample size, neither statistical nor clinical significance was found in the category of 
exercise tolerance and the perceived rate of exertion as measured by the Modified Borg Scale 
over the six week period. The need for an appropriate intervention has been established with 
the findings of numerous international studies that have identified a decrease in exercise 
tolerance of patients diagnosed with PTB (Sivaranjini andVanamail, 2010; Adedoyin et al, 2010; 
Yoshida et al, 2006). Pulmonary rehabilitation has been the main treatment modality in the 
management of Chronic Obstructive Pulmonary Disease (Adedoyin et al, 2010; Yoshida et al, 
2006) but it has been proven that patients with PTB do benefit from the effects of a pulmonary 
rehabilitation programme inclusive of exercise training (Ando et al, 2003; Yoshida et al, 2006). 
The absence of an improvement in the exercise tolerance component of the program may be 
attributed to  the side effects of the HIV  medication which include fatigue, nausea, anxiety 
and depression which a high percentage (67%) of the study population were taking in 
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conjunction with PTB medication (Ciccolo et al, 2004). In light of many physically incompetent 
patients having to walk to the health care facility to receive treatment (Loveday et al, 2007; 
Maguire et al, 2009), the required exercise training will not be performed due to the physical 
disability experienced by the patients (Ando et al, 2003) thus limiting the statistical and clinical 
improvement of exercise tolerance.  
The sub-group of patients undergoing PTB treatment regimen 1 had a greater improvement in 
the distance covered (2.9%) in the 6-min walk test and the rate of perceived exertion (4.65%) 
at the end of the sixth week in comparison to any other sub-groups within the intervention 
group. The sub-group PTB treatment regimen 1 was the only group to show a clinical 
improvement in both the lung parameters tested (refer to section 5.5) and exercise tolerance. 
This result is supported by Kokkola (2009) who also found a similar trend in the correlation of 
lung function and exercise tolerance in patients diagnosed with PTB. The trend between the 
lung function and exercise tolerance as described by Yoshida et al (2006) can be seen as a 
positive indication of the benefits of exercise training as part of a pulmonary rehabilitation 
programme. 
5.6)Conclusion 
This study set out to ascertain whether a home based pulmonary rehabilitation program would 
bring about positive effects of HRQOL, pulmonary function and exercise tolerance. 
Although the home-based pulmonary rehabilitation program in its entirety, as laid out in this 
study, did not yield statistical significance, it did show improvements in some of the 
parameters of HRQOL and Pulmonary function. To this end, the research conducted is a 
positive outcome as these patients would otherwise not have been exposed to any 
intervention other than pharmacological management, to address the morbidity caused by 
PTB. 
Pulmonary rehabilitation with regards to the management of patients diagnosed with PTB is 
beneficial as it not only addresses factors such as lung impairment, social and emotional 
disability but provides a means by which to overcome the aforementioned impairments. 
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Physiotherapists should re-evaluate the current management of patients suffering from PTB as 
well as those with the co-infection of HIV/AIDS. By treating the patient holistically and 
addressing the areas covered in the current study, the goal of achieving the MDG’s will be 
attainable if management of these patients are effectively executed. The clinical implications 
of the current study highlight that there is definitely a strong need in the active role of 
Physiotherapists in the long term care and management of patients with PTB. 
Short term management is no longer efficient in the care of patients in the care of patients 
with PTB. Physiotherapy as a profession now has the responsibility to get involved in the 
holistic management of these patients. Holistic management could possibly include the active 
involvement of physiotherapists in the community by making group treatments available to 
patients that have been diagnosed with PTB.  
Education to patients with PTB would be vital in the role that physiotherapists could play in the 
self-management of patients. These patients will then be able to take better care of 
themselves emotionally as well as physically. 
Assessing the information gathered in the current study, physiotherapist do have a vital role to 
play in the management and treatment of patients diagnosed with PTB and undergoing 
treatment.  
5.7)Limitations and Recommendations 
5.7.1)Sample size 
The current study’s sample size although calculated to obtain statistical significance could have 
been larger to allow generalization. The high number of patients that dropped out after 
meeting initial inclusion criteria also contributed to the small sample size as well asthe impact 
of co-infection of HIV in the current study population could have impacted on the program and 
the parameters which were evaluated.Furthermore only one health care facility was used to 
conduct the study and could also have impacted on sample size.   
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5.7.2)Data Capture sheet 
The researcher developed the data capture sheet herself and although it was piloted some 
areas could have been included to better explain the findings. One such area should have been 
that of the patients HIV/AIDS status. Although not the focus or an objective of the current 
study to ascertain the impact of HIV on PTB, it is probable that it negatively impacted on the 
study findings.  
5.8)Recommendations. 
5.8.1)Sample Size 
Future studies should ensure a larger sample size by recruiting for a longer period, at least 6 
months. Use of multiple health care facilities may ensure a larger population and also allow 
generalization of findings. 
5.8.2)Data Capture Sheet 
Data pertaining to HIV/AIDS status namely, CD4 count, viral load, anti-retroviral treatment 
medication as well as how long the patient was on medication prior to being diagnosed and 
commencing PTB treatment should be included in the future studies’ data capture sheet as a 
high co-infection of HIV with PTB is a reality in the current era.  
  5.8.3) Future Research 
Future research assessing the impact that physiotherapy has on other areas of management of 
patients with PTB should be initiated. It is also recommended that the current research be 
expanded with regards to the sample size and clinical setting. 
  5.8.4) Clinical Practice 
The role of physiotherapists in the management of patients with PTB can be greatly utilized in 
the care and treatment these patients. It would be highly recommended that physiotherapists 
provide the resources by implementing programmes which would facilitate continued 
management of patients with PTB at a community level. Lastly the researcher recommends 
that the area of wellness with regard to patients suffering from PTB be addressed holistically 
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and not just on the pathogen. Pulmonary rehabilitation programs could well be the vehicle 
needed to ensure better outcomes for these patients. 
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Appendix A: Informed consent information 
 
THE INVESTIGATION OF THE EFFECT OF A HOME BASED PULMONARY REHABILITATION PROGRAMME ON THE 
HEALTH RELATED QUALITY OF LIFE OF PATIENTS WITH PULMONARY TUBERCULOSIS. 
 
You are invited to participate in a study that will determine whether a home based exercise programme will have a 
positive effect on your ability to exercise, the functioning of your lungs and how you feel about the health related 
quality of your life. Pulmonary Tuberculosis (PTB) is an air-borne disease that affects the lungs of people that 
contract the disease. The study will give a better understanding of the factors that affect people diagnosed with 
PTB. Factors such as how people with PTB cope in the home environment and how their attitude to their quality of 
life is changed after undergoing a rehabilitation programme based at home. You have been selected to participate 
in the study because of your admission to GF Jooste and the diagnosis of PTB. Should you participate in the study, 
you will be expected to be part of the study for the duration of 6 weeks. The study will include randomly selecting 
patients into two groups. One group will receive a rehabilitation programme to do at home and the other group 
will receive a information leaflet about PTB in addition to the normal medical treatment provided by the hospital. 
The group that did not receive a rehabilitation programme to do at home will receive the programme once the 6 
weeks of the study have been completed. If you are in the group that receives the programme, you will be 
required to perform the rehabilitation programme at home for the duration of 6 weeks. You will be required to 
visit the hospital on the 3
rd
 and 6
th
 week for follow-up testing. A date and time will be arranged for telephonic 
follow-ups that will take place in weeks 1, 2, 4 and 5 to check on your progress with the rehabilitation programme 
and the continuation of the medication. 
 
Procedure: 
The first step will be to complete a questionnaire. You will then perform a simple test with the researcher that will 
test your lung function. The last test that you will have to perform will be a walk test that will measure how far you 
can walk in six minutes. All the tests will be performed in a private area. When you are discharged home, you will 
need to perform an rehabilitation programme for six weeks if you are in that particular group. Should you not 
receive a rehabilitation programme in the first 6 weeks, the researcher will issue you with one after 6 weeks when 
the study has been completed. 
 
Risks and Benefits: 
In doing the walk test, you might experience tiredness, breathlessness and muscle stiffness. If any of the problems 
that you do experience get worse, a doctor will be on call to assist you.  
In participating in the study, you will aid us in finding out whether the home rehabilitation programme improves 
your ability to function at home, improves the way you feel about things in your life and the functioning of your 
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lungs after being diagnosed with PTB. Improvement of the management of PTB in the Western Cape needs to be 
addressed and by participating in the study, you will assist in finding ways to enhance the treatment of people 
diagnosed with PTB in the home environment and change the attitude of those people to their health related 
quality of life. 
 
Confidentiality  
The information obtained from your folder will only be reviewed by the researcher in addition to the staff that 
works at the hospital. The results of the test will also be kept confidential and reviewed only by the researcher. The 
treatment that you will receive from the hospital will not be changed if you do not agree to participate in the 
study. 
Contacts and Questions 
Contact details of the researcher:  
Name: Donna de Grass (masters’ student) 
Contact number: 076 3797828 
 
If you have any further queries you are welcome to contact my supervisor Mrs. Shamila Manie on (021) 
4066628/4066992. 
Research Office: (021) 650 4015 ; Web: www.researchoffice.uct.ac.za: 
 
If you decide to participate in this study, you are free to withdraw at any time without having it affect your stay in 
hospital or the treatment you receive. 
 
You will be given a copy of this form to keep for your records. 
 
Statement of Consent 
 
I have read the above information. I have asked questions and have received answers. I understand the meaning of 
confidentiality; I understand that I have the right to withdraw from the study at any time. I consent to participate 
in the study. 
 
 
Signature________________________ Date ___________ 
 
 
 
Signature of Investigator or Person Obtaining Consent________________________ 
Date ___________   
 
 
 
Signature of independent witness________________________________Date:___________ 
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List of Participants and correlating numbers 
No: Folder Number Phone Number Colour 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
29    
30    
31    
32    
33    
34    
35    
36    
37    
38    
39    
40    
41    
42    
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APPENDIX C: DATA CAPTURE SHEET  
Demographics Data 
Folder number:  ____________________ 
Gender:    Male  [    ]    Female   [    ]        
Date of Birth: 
Body weight:   ____________ kg Height:        _____________ Metres 
Residential Address: 
Population group: 
Black  [   ]  Coloured [   ]  Asian [   ] 
White  [   ]  Indian  [   ] 
Years of formal education:  
None  [   ]  University [   ] 
Grade 7   [   ]  other  [   ] 
Grade 12 [   ] 
Occupation: 
Paid employment  [   ] Retired    [   ] 
Self-employed   [   ] pensioner   [   ] 
Non-paid work (volunteer) [   ] unemployed (health reason) [   ] 
Student   [   ] Unemployed (other reason) [   ] 
Domestic   [   ] Other    [   ] 
     (Please specify) ___________________ 
 
Marital Status: 
Never married  [   ]  Divorced  [   ] 
Currently married [   ]  Widowed  [   ] 
Separated  [   ]  Cohabiting  [   ] 
Co-morbidities: 
Hypertention   [   ] COPD   [   ]           
Diabetes   [   ] Current smoker  [   ] 
Ischaemic heart disease  [   ] HIV/AIDS  [   ] 
Cholesterol [   ] Other                 
(specify)____________________ 
Management: 
Surgical    [   ] Physiotherapy  [   ] 
Pharmacuetical   [   ] 
Admission data 
Date of admission:  ____________________ 
Admission diagnosis: ____________________ 
Confirmed diagnosis: ____________________ 
Date of discharge:   ____________________ 
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APPENDIX A: DATA CAPTURE SHEET  
 Demographics Data 
Folder number: ____________________ Date of admission 
Gender:  Male  [    ]    Female   [    ]        Date of discharge 
Date of Birth: 
Address: 
Body weight: ____________kg  Height: _____________ Metres 
Years of formal education:  
None  [   ]  University [   ] 
Grade 7   [   ]  other  [   ] 
Grade 12 [   ] 
Occupation: 
Paid employment  [   ] Retired    [   ] 
Self-employed   [   ] pensioner   [   ] 
Non-paid work (volunteer) [   ] unemployed (health reason) [   ] 
Student   [   ] Unemployed (other reason) [   ] 
Domestic   [   ] Other    [   ] 
     (Please specify) ________________ 
 
 
 
 
Marital Status: 
Never married  [   ]  Divorced  [   ] 
Currently married [   ]  Widowed  [   ] 
Separated  [   ]  Cohabiting  [   ] 
Co-morbidities: 
Hypertention   [   ] COPD    [   ]  
Diabetes   [   ] Current smoker   [   ] 
Ischaemic heart disease  [   ] Cholesterol   [   ] 
Other (specify)____________________ 
Admission data 
Date of admission:  ____________________ 
Admission diagnosis: ____________________ 
Confirmed diagnosis: ____________________ 
Date of discharge:   ____________________ 
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Iphepha lemibuzo ngezempilo 
 
(Inguqulelo yesiXhosa saseMzantsi Afrika) 
(Xhosa version) 
 
(best available)
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
 
 
2 
 
Beka uphawu kwibhokisi ibenye kwiqela ngalinye echaza imeko yempilo yakho 
namhlanje, kwezi bhokisi zilandelayo. 
 
Musa ukuphawula ngaphezulu kwebhokisi enye kwiqela ngalinye. 
 
Ukuhamba 
Andinangxaki zokuhamba   
Ndinazo ingxakana zokuhamba   
Ndingumlwelwe obopheleleke ebhedini   
 
Ukuzinonophela isiqu 
Andinangxaki zokuzinonophela                                                                  
Ndinazo ingxakana zokuhlamba okanye ukuzinxibisa                                  
Andikwazi ukuzihlamba okanye ukuzinxibisa                                               
 
Izinto zesiqhelo (Umsebenzi, Ukufunda izifundo 
Umsebenzi wasekhaya, Usapho, Ezolonwabo) 
Andinangxaki nokuzenzela izinto zesiqhelo                                  
Ndinazo iingxakana zokuzenzela izinto zesiqhelo                             
Andikwazi kuzenzela izinto zesiqhelo                                                    
 
Iintlungu / Ukungaziva kakuhle 
Andinazintlungu okanye ukungaziva kakuhle   
Ndinentlungwana okanye ukungaziva kakuhle okungephi   
Ndinentlungu ezigqithileyo okanye ukungaziva kakuhle okugqithileyo   
 
Ukuxhalaba / Ukudakumba 
Andinaxhala okanye andidakumbanga                              
Ndibuxhalaba okanye ndibudakumba                               
Ndixhalabe gqitha okanye ndidakumbe gqitha                                                
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Ukunceda abantu ukuze baxele okokuba imeko 
yabo yempilo intle okanye imandundu na sizobe 
isikali (esifana nethemometha). Eyona meko entle 
yempilo iphawulwe ngo-100, eyona meko 
imandundu iphawulwe ngo-0. 
 
Singathanda ubonise kwesi sikali ngokoluvo lwakho 
ukuba impilo yakho intle okanye imandundu 
kangakanani namhlanje. 
Nceda wenze oku ngokuzoba umgca osuka 
ebhokisini engezantsi ukuya kulo ndawo esikalini 
ibonisa ukuba imeko yempilo yakho intle okanye 
imbi kangakanani namhlanje. 
 
 
 
 
 
                                                                                                          
                                                                          
  Ibhokisi 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imeko yempilo 
yakho 
namhlanje 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Eyona meko 
imandundu yempilo 
onokuyiqikelela 
0 
Eyona meko entle 
yempilo 
onokuyiqikelela 
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4 
Njemgoko kunganyanzelekanga ukuba ubhale igama lakho, kodwa ke kuyakunsinceda siqonde 
ngcono iimpemdulo ukuba sinolwazana lwemvelaphi kulowo nalowo umntu njengoko 
zichatshazelwe kule mibuzo ilandelayo 
 
 
1.   Ukhe wabanamava okugula kakhulu na?             Ewe           Hayi 
  Wena   
  Kusapho lwakho   
  Xa ukhathalele abanye   
 
 
2. Mingaphi iminyaka yakho? 
 
 
3. U-  Yindoda Libhinqa 
     
 
 
4. Uyatshaya  
 Wawutshaya  
 Ungumntu ongazange atshaye  
 
 
5. Usebenza, okanye ukhe wasebenza   Ewe Hayi 
       kwiinkonzo zezempilo okanye ezentlalontle?                       
    
 
 Ubusenzani? .......................................................................................... 
 
 
6.    Koku kulandelayo kokuphi okuchaza ngcono  
       okwenzayo? 
  Uyaphangela okanye uyazisebenzela  
  Udla umhlalaphantsi  
  Umsebenzi wasekhaya  
  Umfundi  
  Ufuna umsebenzi  
  Okunye (Chaza)   
 
 
7. Leliphi ibanga ofikelele kulo esikolweni?………………………………………..   
   
 
8. Unesidanga okanye i-diploma Ewe Hayi 
     
 
 
9.    Ukuba uyayazi ikhowudi yeposi yakho nceda uyibhale apha  
   
 
Phawula iibhokisana 
ezifanelekileyo 
Phawula ibhokisana 
efanelekileyo 
Phawula ibhokisana 
efanelekileyo 
Phawula ibhokisana 
efanelekileyo 
Phawula ibhokisana 
efanelekileyo 
 
Phawula ibhokisana 
efanelekileyo 
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  Health Questionnaire 
    
             (South African English version) 
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By placing a tick in one box in each group below, please indicate which statements 
best describe your own state of health TODAY. 
 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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To help people say how good or bad their state of health is, 
we have drawn a scale (rather like a thermometer) on which 
the best state you can imagine is marked 100 and the worst 
state you can imagine is marked 0. 
 
We would like you to indicate on this scale, in your 
opinion, how good or bad your own health is today. Please 
do this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your state of 
health is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
state of health 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst  
imaginable 
state of health 
0 
Best 
imaginable 
state of health 
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4 
Because all replies are anonymous, it will help us to understand your answers better 
if we have a little background data from everyone, as covered in the following 
questions. 
 
 
1. Have you experienced serious illness? Yes No 
  yourself   
  in your family   
  while caring for others   
 
2. What is your age in years ? 
   Male Female 
3. Are you:   
 
4. Are you: 
  a current smoker  
  an ex-smoker  
  a person who has never smoked  
 
5. Do you now, or did you ever, work in Yes No 
 health services or social welfare?   
 
 If so, in what capacity? ..................................................................  
 
6. Which of the following best describes your main activity? 
  in employment or self employment  
  retired  
  housework  
  student  
  seeking work  
  other (please specify)   ............................................ 
    
7. Did your education continue after 
 the minimum school leaving age  Yes No 
 (15 years / grade 9 / standard 7)?   
 
   Yes No 
8. Do you have a degree or a diploma?   
 
9. If you know your postal code, would you please write it here  
 
PLEASE TICK 
APPROPRIATE 
BOXES 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
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APPENDIX : DATA CAPTURE SHEET OF BASELINE AND FOLLOW-UP PARAMETERS 
 
 
 
Lung parameters  baseline Wk 3 
 
Wk 6 
FEV1 
Mean calculation 
 
 
  
FVC 
Mean calculation 
 
 
  
FEV1/FVC 
Mean calculation 
 
 
  
6 Minute walk  baseline Wk 3 Wk 6 
RR at rest 
 
   
Maximal RR    
HR at rest 
 
   
Maximal heart 
rates 
 
   
Borg scale rating 
(RPE) 
   
Distance covered 
 
   
Walking Intensity 
 
   
Telephonic 
follow-ups 
Week one Week two Week four Week five 
Date 
 
    
Time 
 
    
Comments: 
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Regular physical activity is fun and healthy, and increasingly more people are starting to become more active every day.  
Being more active is very safe for most people.  However, some people should check with their physician before they 
start becoming more physically active.  Please complete this form as accurately and completely as possible.
PAR-Q FORM    Please mark YES or No to the following: YES NO
Has your doctor ever said that you have a heart condition and recommended 
only medically supervised physical activity? ____ ____
Do you frequently have pains in your chest when you perform physical activity? ____ ____
Have you had chest pain when you were not doing physical activity? ____ ____
Have you had a stroke? ____ ____
Do you lose your balance due to dizziness or do you ever lose consciousness? ____ ____
Do you have a bone, joint or any other health problem that causes you pain or 
limitations that must be addressed when developing an exercise program 
(i.e. diabetes, osteoporosis, high blood pressure, high cholesterol, arthritis, 
anorexia, bulimia,  anemia, epilepsy, respiratory ailments, back problems, etc.)? ____  ____
Are you pregnant now or have given birth within the last 6 months? ____ ____
Do you have asthma or exercise induced asthma? ____ ____
Do you have low blood sugar levels (hypoglycemia)? ____ ____
Do you have diabetes? ____ ____
Have you had a recent surgery? ____ ____
If you have marked YES to any of the above, please elaborate below:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
Do you take any medications, either prescription or non-prescription, on a regular basis?  Yes/No
What is the medication for? 
How does this medication affect your ability to exercise or achieve your fitness goals?
__________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________
________________________________________________
Please note:  If your health changes such that you could then answer YES to any of the above 
questions, tell your trainer/coach.  Ask whether you should change your physical activity plan.
I have read, understood, and completed the questionnaire.  Any questions I had were answered to my 
full satisfaction.
Print Name: _________________________________Signature: _______________________________________
Date: _______________________________________
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 Home Based Rehab Programme- Check List 
 
IVEKI YOKUQALA 
Imiglalo Yokuzilolonga Iphindwa Ka sets Mvulo Iwesibini Lwesithathu Lwesine Lwesihlanu 
1. Ukuhamba hamba makwenziwe 
yonke imihla 
       
2. Ingqa Zamagxa 10 3      
3. Izangqa Zengalo 10 3      
4. Izangqa Ezinkulu Nezincinci 10 5      
5. Thyala Idonga 10 3      
6. Phakamisa Iziquluba 15 3      
7. Ukolula Izihlunu zamathanga 10 4      
8. Hlala Phantsi umana uphakama 20 4      
9. Ukujiwuzisa Imilenze 10 4      
10. Jiwuzisa Imilenze Emacaleni 
11. Ukuphefumla Ngomlomo Oquthiweyo 
10 2      
12. Ukuphefumla Ngesifuba 10 2      
13. Phemfumla Uhleli Phantsi 10 2      
14. Uhleli Phantsi  2       
15. Umile 2       
16. Ukuvuthele ngamandla 5       
17. Khohlela 5       
 
 
 
        ULANDELO NGOMXEBA: 
UMHLA: 
IXESHA: 
 
10 3   
 
   
  
 
 
 
IVEKI YESIBINI 
Imiolalo Yokuzilolonga Iphindwa Ka sets Mvulo Iwesibini Lwesithathu Lwesine Lwesihlanu 
1. Ukuhamba hamba makwenziwe 
yonke imihla 
       
2. Ingqa Zamagxa 10 3      
3. Izangqa Zengalo 10 3      
4. Izangqa Ezinkulu Nezincinci 10 5      
5. Thyala Idonga 10 3      
6. Phakamisa Iziquluba 15 3      
7. Ukolula Izihlunu zamathanga 10 4      
8. Hlala Phantsi umana uphakama 20 4      
9. Ukujiwuzisa Imilenze 10 4      
10. Jiwuzisa Imilenze Emacaleni 
11. Ukuphefumla Ngomlomo Oquthiweyo 
10 2      
12. Ukuphefumla Ngesifuba 10 2      
13. Phemfumla Uhleli Phantsi 10 2      
14. Uhleli Phantsi  2       
15. Umile 2       
16. Ukuvuthele ngamandla 5       
17. Khohlela 5       
 
 
        ULANDELO NGOMXEBA: 
UMHLA: 
IXESHA: 
 
10 3      
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 Appendix H: Home Based Rehab Programme- Check List 
 
WEEK ONE 
Exercises Repetitions sets Monday Tuesday Wednesday Thursday Friday 
Walking        
Shoulder circles 10 3      
Arm circles 10 3      
Big and small circles 10 5      
Wall press-ups 10 3      
Calf raises 15 3      
Thigh muscle exercising 10 4      
Leg swinging 20 4      
Step side-to-side 10 4      
Pursed lipped breathing 10 2      
Diaphragmatic breathing (in lying) 10 2      
Diaphragmatic breathing (sitting) 10 2      
Postural correction (sitting) 2       
Postural correction (standing) 2       
Coughing 5       
huffing 5       
Sit- to – stand 
 
 
 
TELEPHONIC FOLLOW-UP: 
DATE: 
TIME: 
 
10 3   
 
   
  
 
 
 
WEEK TWO 
Exercises Repetitions sets Monday Tuesday Wednesday Thursday Friday 
Walking        
Shoulder circles 10 3      
Arm circles 10 3      
Big and small circles 10 5      
Wall press-ups 10 3      
Calf raises 15 3      
Thigh muscle exercising 10 4      
Leg swinging 20 4      
Step side-to-side 10 4      
Pursed lipped breathing 10 2      
Diaphragmatic breathing (in lying) 10 2      
Diaphragmatic breathing (sitting) 10 2      
Postural correction (sitting) 2       
Postural correction (standing) 2       
Coughing 5       
huffing 5       
Sit- to – stand 
 
TELEPHONIC FOLLOW-UP 
DATE:  
TIME: 
 
10 3      
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WALKING must be done daily  
 
15 min walking on a level surface should be done everyday 
 
 
SHOULDER CIRCLES (3x10 rest for 30 counts) 
 
Without moving the arm, move the shoulder in circles, 
trying to brush the ear. 
Repeat with the opposite arm 
 
 
 
ARM CIRCLES (3x10, rest for 30 counts) 
 
Now using the whole arm, move the arm in circles, trying to 
brush the ear with the arm 
Repeat  with the other arm 
 
 
 
 
BIG AND SMALL CIRCLES (10x5 times per arm, rest for 
30 counts) 
 
The arms will be placed at shoulder level with the arms 
moving from that position to make big circles for 10 counts, 
from that position make smaller circles for 10 counts 
Repeat with the other arm. 
 
WALL PRESS-UPS( 3x10, rest for 30 counts) 
 
Stand half arms length away from the wall with hands on 
the wall, feet shoulder width apart. Do a push up against 
the wall with the back straight, using just the arms.  
 
 
CALF RAISES (15x3, rest for 30 counts) 
 
Stand with feet shoulder width apart, go up onto your toes, 
balance for 5 counts then return to the starting position. 
You can hold onto the wall for support 
 
  
THIGH MUSCLE EXERCISING (4 times, rest for 30 sec) 
 
Sit in a chair with both legs bent at the knee. Bend one leg 
till its straight and keep for 10 counts. Return to the starting 
position. Repeat with the other leg 
 
 
SITTING TO STANDING (10x3, rest for 30 counts) 
 
Sit on a chair with both feet on the ground, move from 
sitting to standing 10 times 
 
 
LEG SWINGING (20x4 times each leg, rest for 30 
counts) 
 
Use a table for support with one hand on the table; swing 
the opposite leg forwards and backwards. Perform 20 times 
and then change sides. Repeat four times 
 
 
STEP SIDE TO SIDE (10x4 times, rest for 30 counts) 
 
Standing on a level surface, step to the left and bring feet 
together, step to the right and bring feet together.  
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Pulmonary Rehabilitation: 
 
 
 
PURSED LIPPED BREATHING (10 times, 20 sec rest) 
 
Sitting in a comfortable position, arms either next to your side 
or in your lap pretend you will be blowing bubbles into the 
space before you. Breathe all your air out until you can’t do it 
anymore and breathe in. rest for 10 counts and perform the 
exercise 10 times 
 
 
DIAPHRAGMATIC BREATHING ( WITH FACILITATION) 
 
 
 
Laying on your stomach (perform 10 times) 
 
Place your hands on your stomach feeling how you breathe 
from your stomach and not from your chest. Repeat the 
exercise 10 times 
 
 
In sitting: (perform 10 times) 
 
Perform the same breathing exercise in sitting with your 
hands on your stomach and breathe in and out for ten counts
  
 
 
POSTURAL CORRECTION 
 
 
 
 
In sitting ( perform twice) 
 
Check that your chin is not poking forward, shoulders are 
pushed back, chest is pushed forward and you can feel your 
sitting bones on the chair 
 
 
 
 
In standing (perform twice) 
 
Check that your chin is not poking forward, your shoulders are 
pushed back, back is straight and hips are level. 
 
 
COUGHING AND HUFFING 
 
 
 
 
 
Huffing (repeat 5 times) 
 
Place hands on your stomach in sitting, breathe from your 
stomach for 3 counts and then breathe out very hard, forcing 
the air out of your lungs 
 
 
 
 
Coughing ( repeat 5 times) 
 
Place hands on your stomach, breathe from your stomach till 
the count of 3 and cough hard from your stomach as you have 
been practicing with the breathing 
 
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
Appendix I: Exercise Programme 
The exercise programme prescribed to the participants included into the intervention group for 
the period of six weeks and thereafter for the control group to complete at the end of the 
intervention period. The exercise programme comprised of four components, was designed to 
meet the needs of the patients diagnosed with Pulmonary Tuberculosis (PTB). The four 
components namely: (1) Cardiovascular (2) Upper limb strengthening (3) Lower limb 
strengthening (4) Pulmonary rehabilitation. The exercises incorporated into the programme 
were all low impact exercises that enabled the participant to perform the exercises with 
minimal strain on the participants who experienced severe side-effects from the PTB and ARV 
medication (Loveday et al, 2007). The exercise programme was translated into Xhosa as well as 
Afrikaans which was tested during the pilot study to ensure the patients understood the 
exercise they were required to perform. Below a detailed explanation of each exercise will be 
given as well as the prescribed administration of each activity. 
1. Cardiovascular Component: 
Wedzicha (1998) and Yoshida (2006) recommended rehabilitation programmes should 
have a cardiovascular component when implementing a rehabilitation programme. The 
participants were required to walk for a duration of 15 minutes on a daily basis. The 
intensity was set at 60-75% of the reserve heart rate. The majority of the participants 
did not understand the concept increasing their measured Heart Rate (HR) accordingly. 
The instruction to the participant was then changed to increasing the speed of their 
walking each day. 
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2. Upper limb strengthening 
The addition of upper limb exercises into the exercise programme aimed to improve the 
participants ability to perform activities of daily living (ADL) within the household and at 
work if employed. 
(a) Shoulder Circles 
Sets: 3; Repetitions: 10; Resting Period: 30 seconds 
The participant was required to perform circles with the shoulders without moving the arms. 
The instruction to the participant was to try to brush the ear with the shoulder. The same 
action was required to be performed with the opposite arm for the same number of sets and 
repetitions 
(b) Arm Circles 
Sets: 3; Repetitions: 10; Resting Period: 30 seconds 
The participant was required to move the arm in the full Range of Motion (ROM) through 
flexion into extension according to the prescribed number of sets and repetitions 
(c ) Big and Small Circles 
Sets: 5; Repetitions: 10; Resting Period: 30 seconds 
The arm was required to be placed at shoulder level with small circles being performed for 10 
counts. The participant was then required to increase the width of the circle to perform the 
same action with a bigger circle for the same number of counts. This was counted as one set. 
The same had to be repeated with the opposite arm. 
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(d) Wall press-ups 
Sets: 3; Repetitions: 10; Resting period: 30 seconds 
The participant was required to make use of a wall to perform the activity. They were required 
to stand half a arms length from the wall and perform a press-up against the wall for the 
prescribed number of sets and repetitions 
3. Lower limb strengthening 
The addition of lower limb strengthening activities aimed to improve the participants 
walking ability and improve any problems that might be associated with the component of 
walking and general mobility 
(a) Calf Raises  
(Sets: 3; Repetitions: 15; Resting Period: 30 seconds) 
The participant was required to use a chair or walk as a support to perform the activity. It 
was required that the participant stand with the feet shoulder width apart and raise up as 
far as possible onto the toes. The position had to maintained for 5 seconds and then return 
to the starting position. This had to be done according to the prescribed number of sets and 
repetitions 
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(b) Quadriceps Strengthening  
(Sets: 4; Holding Period: 10 seconds; Resting Period: 30 seconds). 
The participant was required to sit in a chair with both legs bent at 90 degrees at the knee. 
The participant was then required to straighten the knee till the knee was straight and hold 
it there for the holding period of 10 counts. The same had to be repeated for the opposite 
limb. 
(c) Sitting to Standing 
Sets: 3; Repetitions: 10; Resting period: 30 seconds 
The participant was required to be seated in a chair that would enable the participant to 
have the knees bent at 90 degrees. The motion moving from sitting to the standing position 
had to be performed in a slow controlled manner and back to the starting position. The 
action incorporated all the lower limb muscles as well as postural muscles in moving from 
sitting to standing. 
(d) Leg Swinging 
Sets: 4; Repetitions: 20; Resting period: 30 seconds 
A table or chair was required to provide the participant with the necessary support while 
performing the activity. One hand was used for support on the table or chair while the leg 
furthest away from the supporting structure was moved backward and forward in a 
controlled manner for the prescribed number of sets and repetitions. The same was 
repeated for the opposite limb. 
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(e) Leg swinging from side to side 
Sets:4; Repetitions: 10; Resting period: 30 seconds 
The same movement was required from the participant as described in Leg Swinging (Point 
d) with the participant now facing the supporting structure. The starting point was in the 
center of the supporting structure. The participant was required to abduct the moving limb 
in a controlled manner till the limb was not able to move any further. The participant was 
required to perform the activity for the prescribed number of sets and repetitions and 
repeat the activity for the opposite limb. 
Pulmonary Rehabilitation: 
(a) Pursed Lipped Breathing 
Sets:1; Repetitions: 10; Resting period: 20 seconds. 
The participant had to seated in a comfortable position with arms on either side of the 
trunk or placed in the lap. Inhalation was to be performed through the nostrils. The 
instruction given to the participant for exhalation with pursed lips: Imagine blowing bubbles 
into the air until all the air in your lungs is finished. Exhalation was to continue until the 
participant could no longer perform the task 
(b) Diaphragmatic breathing with facilitation 
Diaphragmatic breathing was illustrated to each participant recruited into the intervention 
group. The breathing activity was to be performed in the lying position as well as in sitting. 
Facilitation was performed with the hands placed on either side of the diaphragm, 
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performing the activity as demonstrated by the therapist. The activity was to be repeated 
lying and sitting for 10 repetitions. 
(c) Postural Correction 
Poor posture was demonstrated to participants included into the study and the posture of 
each participant was corrected in both sitting and standing. The participant was then 
instructed how to correct the incorrect posture on a daily basis.  
(d) Coughing and Huffing: 
Diaphragmatic breathing was incorporated into the activity of huffing as well as coughing. 
When huffing, the participant was instructed to force the air out of the stomach while 
performing diaphragmatic breathing for three counts. The same instruction was given when 
performing the coughing component. Precautions were given to the participant to be in a 
well ventilated area when performing the breathing activities. 
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Ukuzilolonga Emzimbeni Kwasekhaya 
 
 
Ukuhamba Hamba Makwenziwe Yonke Imihla 
 
Ukuhamba hamba kwindawo emthebelele makwenziwe yonke 
imihla kangange mizuzu elishumi elinesihlanu 
 
 
Izangqa Zamagxa (Bala amashumi amathathu uphumle 
ngokubala uyokufika kumashumi amathathu) 
 
Yenza Izangqa ngamagxa, ungazishukumisi ingalo, uzame 
ukukrweca undlebe ngamagwa. Yenza kwicala ngalinye icala 
ubelinge ngexesha ulandelise ngelinge 
 
 
Izangqa zengalo (Bala amashumi amathathu uphumle 
ngokubala uyokufika kumashumi amathathu) 
 
Sebenzisa ingalo yonke. Jikelezisa ingalo yonke uzame ukukrweca 
indleble. Ingalo Kufuneka uyikhupne ecaleni ime nqo ibengathi 
ukhombe ecaleni. Yenzanjalo nakwelinye icala 
 
 
 
Izangqa Ezinkulu Nezincinci (Bala uyokufika kwishumi kahlanu 
kwingalo nganye, uphumle ngokubala uyokufika kumashumi 
amathathu) 
 
Misa ingalo ilingane ncligxa wenze izangqa ezinkulu ubale 
kalisshumi. Emvakoko bala kalishumi usenza izangqa ezincinci. 
Yenza njalo nakwelinye icala 
 
Thyala Idonga (Thyala kathathu ubala kalishumi ngexesha. 
Phumla ngokubala uphele kumashumi amathathu yima phambi 
kodonga) 
 
Ingqiniba zakho zibesema caleni izandla zibesedongeni. Vula 
imilenze ilingane namagxa yima nqo uthyale nqezandla zodwa 
 
Phakamisa iziquluba (Phakamisa Kathathu ubala kalishumi 
ngexesha elinye. Phumla ngokubala uyokufika kumashumi 
amathathu) 
 
Vula imilenze ilingane namagxa, ngcotsha ubale kahlanu uyeke. 
Ungabambelela nasedongeni ukuba uyoyisakala. 
  
Ukolula Izihlunu Zamathanga (Yenza kane uphumle ngokubala 
uyokufika kumashumi amathathu) 
 
Hlala phantsi esitulweni ugobe amadolo zide inyawo zinyathele 
phantsi. Phakamisa umlenze ubemnye ume nqo, bala kalishumi 
uhleli njalo. Wubeke phantsi wenze omnye umlenze 
 
Hlala Phantsi Umana Uphakama (Yenza kathathu ubala 
kalishumi ngexesha phumla ngokubala uphele kumashumi 
amathathu) 
 
Hlala phantsi esitulweni inyawu zakho zingajingi, mana uphakama 
uphinde uhlale phantsi kalishumi 
 
 
Ukujiwuzisa Imilenze (Yenza kane ubala uyokuma kumashumi 
amabini ngexesha kumlenze ngamnye, phumla ngokubala 
uyokuma kumashumi amathathu) 
 
Funa indawo yokubambelela nokuba yitafile. Bambelela ngesandla 
esinye. Jiwuzisa umlenze (uwuse phambili nangasemva) Bala 
kangangamashumi amabini. Tshintsha wenze ngomaye umlenze 
 
Jiwuzisa Imilinze Emacaleni (Yenza kane ubala amashumi 
amabini ngexesha elinye phumla ngokubala iyokuma 
kumahumi amathathu) 
 
Yima, phakamisa umlenze wasekhohlo uwuse ecaleni uwubuyise 
emva koko uwubeka phamtsi. Wenze njalo nakumlenze 
wasekunene 
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Ukuzilolonga Emzimbeni Kwasekhaya 
 
 
 
Ukuphefumla ngomlomo oquthiweyo (Yenza kalishumi 
uphumle ngokubala uyokuma kumashumi amabini) 
 
Hlala ngendlela ekwanelisayo, ingalo emacaleni okanye 
phezu kwakho, yenza ngathi uzukuvuthela amaqam emoyeni, 
phefumla wonke umoya onawo de ungakwazi ukuphefumla, 
bizela umphefumlo. Phumla ngokubala kalishumi uphinde 
uvuthele njengasekuqaleni. Phinda phinda kude kubelishumi 
 
UKUPHEFUMAL NGESIFUBA (LONGA INDLELA OPHEFUMLA NGAYO) 
 
 
 
Lala ngomqolo (Yenza kalishumi) 
 
Beka izandla zakho esuswini umamele ukuba uphefumla njani 
ngesisu, hayi ngesifuba. Phinda kalishumi 
 
Phefumla Uhleli Phantsi (Yenza Kalishumi) 
 
Yenza ngalendlela yokuphemfumla ngesisu. Hlala phantsi 
beka izandla zakho esiswini phefumla ngokubizela umoya 
phinde uwukhuphe. Yenza kalishumi 
 
 
UKULUNGISO INDLELA YOKUMLALA OKANYE YOKUMA 
 
 
 
 
Uhleli Phantsi (Yenza Kabini) 
 
Isilevu sakho masingayi phambili, amagxa makaye ngemva 
isifuba siyephambili 
 
 
 
Umile (Yenza Kabini) 
 
Isilevu sakho masingayi phambili, amagxa akho dyengemva 
umqolo wakho ubenqo namathanga alingane 
 
UKUKHOHLELA/ UKUVUTHELA NGAMANDLA 
 
 
 
 
 
Ukuvuthele ngamandla ( Phunda Kahlanu) 
 
Beka izandla zakho esisiwini uhleli phantsi. Phefumla ngesisu 
ubale kathathu, phemfumla/ vuthela ngamandla unyanzela 
umoya uphume kumaphaphu akho 
 
 
 
Khohlela (Phinda Kahlanu) 
 
Beka izandla esisiwini, phefumla ngesisu ubale kathathu 
khohlela ngamandla ngesisu njengoka ubuphefumla ngesisu 
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Appendix J: 15-Grade Borg scale 
 
15-Grade Borg scale for rating perceived exertion: 
6 No exertion at all 
7 Extremely light 
8  
9 Very light 
10  
11 Light 
12  
13 Somewhat hard 
14  
15 Hard (heavy) 
16  
17 Very hard 
18  
19 Extremely hard 
20 Maximal exertion 
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15-Amabanga Okutshintsha Khesikali iBorg 
 
Amabonga atshintseleyo esikali seborg ejonga imisebenzi yomzimba nengqondo 
ecingelwayo 
 
6 Akukho Mahluko 
7 Umahluko Umncinci Kakhulu 
8  
9 Umahluko umnanci 
10  
11 Umahluko awaumncincananga kangako 
12  
13 Ubunzinyana 
14  
15 Ubunzima 
16  
17 Ubunzima Kakhulu 
18  
19 Ubunganyamezeleki ubukwelona 
nqanaba 
20 Liphezulu lobundzima 
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Background: 
Pulmonary Tuberculosis (PTB) is a bacterial infection. It is spread by inhaling tiny 
droplets of saliva from the coughs or sneezes of a person that already has PTB. 
Mycobacterium tuberculosis is the bacteria responsible for TB. It is very slow 
moving, so a person may not experience any symptoms for many months, or even 
years, after becoming infected. TB primarily affects the lungs (pulmonary TB). 
However, the infection is capable of spreading to many different parts of the body, 
such as the bones or nervous system.  
Symptoms: 
Tuberculosis (TB) will not cause any symptoms until the infection has reached the 
lungs. As the bacteria are very slow moving,  the symptoms might not begin for 
many years after the initial exposure to the bacteria has taken place. Symptoms of 
pulmonary tuberculosis include: 
 a persistent cough that brings up phlegm (thick mucus), which may be 
bloody 
 breathlessness: difficulty breathing get worse  
 weight loss 
 loss of appetite 
 fever: a temperature of 38°C or above 
 feeling of always being tired 
 a general sense of not feeling well 
Diagnosis: 
 A diagnosis of PTB can usually be confirmed by carrying out a chest X-ray. If you 
have a PTB infection, there should be changes to the appearance of your lungs that 
will be visible on the X-ray. Samples of your mucus and phlegm (sputum samples) 
will also be taken and studied under a microscope for the presence of TB bacteria. 
Treatment: 
If you are diagnosed with active pulmonary tuberculosis (TB), you will be sent to a 
health care facility. A person that will supervise your medication, usually a nurse or 
a health visitor, will be your point of contact between you and the rest of the team 
and will help with the treatment process.  It is very important that you take your 
medicines exactly as prescribed, and that you complete the whole course of 
antibiotics. If you stop the medication before you have completed the course, or if 
you skip a dose, the TB infection may become resistant to the medication. This is 
known as multi-drug resistant tuberculosis (MDR-TB) and it is potentially very 
serious, and can be challenging to treat.  
Multi-Drug Resistant Tuberculosis: 
However, there are an increasing number of cases where tuberculosis develops a 
resistance to two antibiotics. This is known as multi-drug resistance tuberculosis 
(MDR-TB), and tuberculosis develops a resistance to three or more antibiotics. This 
is known as extensive multi-drug resistance tuberculosis (XDR-TB). MDR-TB and 
XDR-TB will usually require between 18 and 24 months of treatment, using a 
combination of four different antibiotics. If you have one of these conditions, you 
may be referred to a specialist TB clinic for treatment and monitoring as they are 
harder to treat. 
Preventing the spread of infection: 
 Always cover your mouth when coughing, sneezing or laughing. 
 Carefully dispose of any used tissues in a sealed plastic bag. 
 Open windows when possible to ensure a good supply of fresh air. 
 Stay away from work, school or college until your TB treatment team 
advises you that it is safe for you to return. 
 Avoid sleeping in the same room as other people because you could cough 
or sneeze in your sleep without realizing it. 
References: 
Campbell IA, Bah-Sow O. Pulmonary tuberculosis: diagnosis and treatment. BMJ 
2006; 332:1194-1197, doi: 10.1136/bmj.332.7551.1194 
WHO. WHO Report 2008, Global tuberculosis control - surveillance, planning, 
financing 2008 
Information for patients with Pulmonary 
Tuberculosis (PTB) 
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Isifo sephepha yemithambo siyintsholongwane eyosulelayo sisasazeka 
ngokuphefumla(bizela) amaqabaza amathe asuka kumntu ose esuleleke sisifo 
sephepha ngokuthi akhohlele okanye athimle. Isifo sephepha esibizwa 
mycobacterium siyintsholongwane abangela isifp sephepha. Impawo zesisifo 
zithatha ixesha elide ukuqapheleka ingazi nyanga okanye iminyaka. Esisifo siqala 
ngokuhlasels kodwa siyakwazi ukunwenwela emathankjeni okanye Inervous 
system. 
Impawu  
Isifo sephepha asibonakalisi zimpawo de sihlasele imiphunga. Impawu zesisifp 
zivela kade kuba intsholongwane ithatha ixesha elide ukubonakala emva kokuda 
umntu esulelwe ngesisifo. Nazi ezinye impawu zesisifo: 
 Ukukhohlela ixesha elide elinezikhohlela ezinegazi ngamanye amaxesha 
 Ukuphefumla nzima ubengathi uphelelwa ngumoya 
 Ukuhla emzimbeni 
 Xa amaqondo obushushu bomzima engaphezu ko 38’C 
 Ukuziva udiniwe maxesha onke 
 Ukungaziva mnandi ibengathi uyagula 
Ufunyaniso Lwesigulo  
Ixilingo lwesifuba ngesizobo I x-ray luyinqginiseko lokufunyanwa kwesifo sephepha. 
Xa ufunyanwe unesisifu, imiphunga yakho ibanotshintsho xa ijongwe kwi x-ray. 
Kuye kuthathwe imifinya okanye izikhohlela zakho ziyokujongwa zifundwe phantsi 
kwemicroscope kujongwa ubukho balentsholongwane yesifo sephepha. 
Amayeza Anceda Esisifo  
Ukuba ufunyaniswe unesisifo sephepha siphila kuwe uye uthunyelwe kwindawo 
ekhathaleze impilo. Uye unikwe unompilo okanye umongikazi qzakukonga ukuba 
uyawatya amayeza akho akunxulumanise nezinye izigulane ezinesisifo ukwenza 
ukuphila kubengcono kubaluleke kakhulu ukuba uwathathe ngenolela ubuyalelwe 
ngayo amayeza akho ugqibe nexesha ubulinikiwe lokuwasebenzisa lamayeza 
ubuwanikiwe. Ukuba akuligqibanga ithuba ubulinikiwe lokusela amayeza okanye 
umana uqakatha intsuku esisifo sephepha siye siwanyamezele/ siwalwe amayeza. 
Lento ke iye ibizwe imulti-drug resistant TB: le MDR-TB inobunzima kwaye 
inobuzaza ekuyinyangeni. 
MDR-TB: 
Amanani aya ngokwenyuka apho kufunanyiswa ukuba iTB ilwa ukunyangwa kwi i-
antibiotics ezimbini. Kwaye lento ibizwa i MDR-TB. Esisifo siyakwazi ukulwa 
sinyamezele ukunyangwa ngeantibiotics ezintathu nanga phezulu, lena ke ibizwa 
XDR-TB. Kwaye ifuna unyango oluthatha inyanga eziushumi elinesibhozo ukuya 
kumashumi amabini anesine kusetyenziswa iantibiotics ezine ezahlukileyo. Ukuba 
ufunyaniswe uphantis kwenye yezimeko uye uthunyelwe ikliniki ekhethelwe bucala 
ukuphilisa ukwenza ngcono nokujonga impilo yakso kuba inobuzaz ukukuphilisa 
kubu ukwelinye lenqanaba lokosuleleka. 
Ukunqanda ukosuleleka Kwesisifo 
 Beka isandla emlonyeni ngamaxesha onke xa ukhohlela, uthimla okanye 
uhleka 
 Amaphepha okufinya/okosula asebenzileyp funeka 
Uwafake kwisingxobo seplastiki esivalekayo ngononophelo 
 Ifestile funeka zivuliwe xa kunyanzelekile kuzokufumaneka impepho 
efunekayo 
 Hlukana nokuya emsebenzini esikolweni okanye esikolweni semfundo 
ephakamileyo de amcebisi wakho ngonyango akucebise ukuba ungabuyela 
 Zama (Baleka) ngandlela zonke ungalau kwigumbi lokulala elinye nabanye 
abantu kuba kungenzeka ukhohlele okanye uthimle ulele 
 
 
 
 
 
Isiqinisekiso: 
Campbell IA, Bah-Sow O. Pulmonary tuberculosis: diagnosis and treatment. BMJ 2006; 
332:1194-1197, doi: 10.1136/bmj.332.7551.1194 
WHO. WHO Report 2008, Global tuberculosis control - surveillance, planning, financing 2008 
 
Incukacha yezigulane ezinesifo sephepha 
yemithambo 
Imvelaphi  
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C ITY HEAL TH -C~yHealth 
2009-10-23 
re: Research Proposal: The effect of a home based pulmonary rehabilitation 
program on cardiovascular fitness and exercise tolerance of patients diagnosed 
with pulmonary tuberculosis (lD No: 10154) 
Dear Ms Manie 
Your email dated 16/10/2009 refers. 
Permission is hereby granted for Ms De Grass to conduct the research as set out in the 
protocol at Ubuntu Clinic in Khayelitsha. 
Contact People: Khayelitsha Sub District 
Dr V de Azevedo: Sub District Manager 
Tel/Cell: (021) 360-125/0836293344 
Mr T Mhlubulwana: PHC & Programme Manager 
Tel/Cel l: (021) 360-1153 / 082 715 0147 
Please note the following: 
1. All individual patient information obtained must be kept confidentiaL 
2. Access to the clinic and its patients must be arranged with the relevant Managers such 
that normal activities are not di rupted . 
3. A copy of the final report must be sent to City Health Head Office (P. O. Box 2815, 
Cape Town 8001) within 3 months of its completion and feedback must also be given 
to the clinic involved. 
4. Your project has been given an 10 number (10154). Please use this in any future 
correspondence with us. 
Thank you for your co-operation and contact me if you require further assistance. 
Yours sincerely 
Lzj/IP~ 
Dr G H Visser 
Manager: Specialised Health 
cc Dr de Azevedo & Mr Mhlubulwana 
Dr Jennings 
Ms Caldwell 
THIS CITY WORKS FOR YOU ESI SIXEKO SISEBENZELA WENA HIERDIE STAO WERK VIR JOU 
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UNIVERSITY OF CAPE TO\X'N 
15 July 2009 
REC REF: 251/2009 
MsDDEGrass 
School of Health & Rehab 
Dear I\Is De Grass 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
e-mail: sumayab.ariefdien@Uct.ac.za 
PRO]ECI' TITLE: THE EFFECTS OF A HOME BASED PULMONARY REHABILITATION 
PROGRAMME ON CARDIOVASCULAR FUNCTION AND EXERCISE TOLERANCE OF 
PATIENTS DIAGNOSED WITH TUBERCULOSIS 
Thank you for submitting yout study to the Researcb Ethics Committee for review. 
It is a pleasute to inform you that the Ethics Committee has formally approved the above-mentioned study. 
Approval is granted for one year till the 20th July 2010. 
Please submit an annual progress report if the researcb continues beyond the expiry date. Please submit a brief 
summary of findings if you complete the study wi thin the approval period so that we can close Out file. 
Please note one minor correction: please provide the contact details for the Human Research Ethics 
Committee (professor Marc Blockman:021 40 6633 8)rather than those of the Research 0 flice. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the REC. REF in all your correspondence. 
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Yours slflcerely 
PROFESSOR M BLOCKMAN 
CHAIRPERSON. HSF HUMAN ETH 
Federal \'(Tide Assurance Number: F\l(T AOOOO 1637. 
Institutional Review Boat<! (IRB) number: IRBOOOO 1938 
1bis selves to confinn that the University of Cape Town Research Ethics Committee complies to the Ethics 
Standards for Clinical Research with a new drug in patients, based on the Medical Research Council (l'I-ffi.C-
SA), Food and Drug Administration (FDA-USA), International Com-ention on Harmonisation Good Clinical 
Practice (I CH GCp) and Declaration of Hdsinki guidelines. 
The Research Ethics Committee granting this approval is in compliance with the ICH Harrnonised Tripartite 
Guidelines &S: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) and FDA Code Federal 
Regulation Part 50, 56 and 312. 
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